

ПЕРЕЧЕНЬ ЛИТЕРАТУРЫ ИСПОЛЬЗОВАННОЙ ПРИ ПОДГОТОВКЕ КНИГИ

1. Abouya YL, Beaumel A, Lucas A, et al. *Pneumocystis* pneumonia—an uncommon cause of death in African patients with acquired immunodeficiency syndrome. *Am Rev Respir Dis.* 1992;145:617–620.
2. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Bein Community Programs for Clinical Research on AIDS. *N Engl J Med.* 1994;330:657–662.
3. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. *N Engl J Med.* 1994;330:657–662.
4. Abrams DI. AIDS-related lymphadenopathy: The role of biopsy. *J Clin Oncol.* 1986;4:126–127.
5. Agarwala S, Mummaneni V, Randall D, Geraldles M, Stoltz R, O'Mara E. Pharmacokinetic (PK) Effect of Rifabutin (RIF) on Atazanavir (ATV) with and without Ritonavir (RTV) in Healthy Subjects. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 24–28, 2002, Abstract 445-W.
6. Agarwala S, Russo R, Mummaneni V, Randall D, Geraldles M, O'Mara E. Steady-State Pharmacokinetic (PK) Interaction Study of Atazanavir (ATV) with Ritonavir (RTV) in Healthy Subjects, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27–30, 2002, Abstract H-1716.
7. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. *FASEB J.* 1996b;10:258–266.
8. Ahmad A, Menezes J. Defective killing activity against gp120/41-expressing human erythroleukaemic K562 cell line by monocytes and natural killer cells from HIV-infected individuals. *AIDS.* 1996a;10:143–149.
9. Albert SM, Marder K, Dooneief G, et al. Neuropsychologic impairment in early HIV infection. *Arch Neurol.* 1995;52:525–530.
10. Albrecht M, Katzenstein D, Bosch R, Liou S, Hammer S. ACTG 364: virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFZ) in combination with new nucleoside analogs in nucleoside experienced subjects (subj). Abstract 489. 6th Conference on Retroviruses and Opportunistic Infections. Jan 31–Feb 4, 1999; Chicago.
11. Alcibes P, Munoz A, Vlahov D, Friedland GH. Incubation period of human immunodeficiency virus. *AIDS.* 1993;15:303–318.
12. Alkhatib G, Broder CC, Berger EA. Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. *J Virol.* 1996;70:5487–5494
13. Alkhatib G, Combadiere C, Broder C, et al. CC CKR5: A RANTES, MIP-1 α , MIP-1 β receptor as a fusion cofactor for macrophage-tropic HIV-1. *Science.* 1996;272:1955–1958
14. Allain JP, Laurian Y, Paul DA, Senn D. Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. *Lancet.* 1986;2:1233–1236.
15. Allegra CJ, Chabner BA, Tuazon CU, et al. Trimetrexate for the treatment of *Pneumocystis carinii* pneumonia in patients with the acquired immunodeficiency syndrome. *N Engl J Med.* 1987;317:978–985.
16. Allen S, Lindan C, Serufila A, et al. Human immunodeficiency virus infection in urban Rwanda: Demographic and behavioural correlates in a representative sample of child bearing women. *JAMA.* 1991;266:1657–1663.
17. Alonso K, Pontiggia P, Medenica R, et al. Cytokine patterns in adults with AIDS. *Immunol Invest.* 1997;26:341–350
18. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. *Science.* 1996;274:94–96.
19. Amadori A, Chieco-Bianchi L. B-cell activation and HIV-1 infection: Deeds and misdeeds. *Immunol Today.* 1990;11:374–379.
20. American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus type 1 (HIV-1) infection. *Neurology.* 1991;41:778–785.
21. Anderson DJ, Hill JA. CD4 (T4+) lymphocytes in semen of healthy heterosexual men: Implications for the transmission of AIDS (Letter). *Fertil Steril.* 1987;48:703–704.
22. Anderson DJ, O'Brien TR, Politch JA, et al. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. *JAMA.* 1992;267:2769–2774.
23. Anderson DJ, O'Brien TR, Politch JA, et al. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. *JAMA.* 1992;267:2769–2774.

24. Andiman WA, Silva TJ, Shapiro TD, et al. Predictive value of the human immunodeficiency virus 1 antigen test in children born to infected mothers. *Pediatr Infect Dis J.* 1992;11:436–440.
25. Anonymous: Needlestick transmission of HTLV-III from a patient infected in Africa. *Lancet.* 1984;2:1376–1377.
26. Anthony JC, Vlahov D, Nelson KE, et al. New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. *Am J Epidemiol.* 1991;134:1175–1189.
27. Antinori A, Ammassari A, DeLuca A, et al. Diagnosis of AIDS-related focal brain lesions: A decision making analysis based on clinical and neurological characteristics combined with polymerase chain reaction assays in CSF. *Neurology.* 1997;48:687.
28. Aptivus [package insert]. Boehringer Ingelheim GmbH, Germany; 2005.
29. Armstrong J, Horne R. Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy. *Lancet* 1984;2:370–372.
30. Arthur LO, Bess JW Jr, Sowder RC II, et al. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. *Science.* 1992;258:1935.
31. Ascher M, Sheppard H. AIDS as immune system activation: A model for pathogenesis. *Clin Exp Immunol.* 1988;73:165–167.
32. Ascher MS, Sheppard HW. AIDS as immune system activation. II. The panergic immnesia hypothesis. *J Acquir Immune Defic Syndr.* 1990;3:177–191.
33. Atkins MC, Carlin EM, Emery VC, et al. Fluctuations of HIV load in semen of HIV positive patients with newly acquired sexually transmitted diseases. *BMJ.* 1996;313:341–342.
34. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4⁺ T cell homeostasis and function in advanced disease. *Science.* 1997;277:112–116.
35. Ayres L, Avillez F, Garcia-Benito A, et al. Multicenter evaluation of a new recombinant enzyme immunoassay for the combined detection of antibody to HIV-1 and HIV-2. *AIDS.* 1990;4:131–138.
36. Bacchetti P, Moss AR. Incubation period of AIDS in San Francisco. *Nature.* 1989;338:251–253.
37. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. *Neurology.* 1994;44:1892–1900.
38. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. *Neurology.* 1994;44:1892–1900.
39. Badaro R, DeJesus E, Lazzarin A, Jemsek J, Clotet B, Rightmire A, Thiry A, Wilber R. Efficacy and Safety of Atazanavir (ATV) with Ritonavir (RTV) or Saquinavir (SQV) Versus Lopinavir/Ritonavir (LPV/RTV) in Combination with Tenofovir (TFV) and One NRTI in Patients Who Have Experienced Virologic Failure to Multiple HAART Regimens. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, July 13-16, 2003. Abstract 118.
40. Baggiolini M, Moser B. Blocking chemokine receptors. *J Exp Med.* 1997;186:1189–1191.
41. Bagnarelli P, Menzo S, Valenza A, et al. Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. *J Virol.* 1992;66:7328–7335.
42. Baldwin GC, Fleischmann J, Chung Y, et al. Human immunodeficiency virus causes mononuclear phagocyte dysfunction. *Proc Natl Acad Sci U S A.* 1990;87:3933–3937.
43. Balslev E, Thomsen HK, Weismann K. Histopathology of acute human immunodeficiency virus exanthem. *J Clin Pathol.* 1990;43:201–202.
44. Banda NK, Bernier J, Kurahara DK, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. *J Exp Med.* 1992;176:1099–1106.
45. Bardsley-Elliott A and Perry CM. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. *Paediatric Drugs.* 2000;2(5):373-407.
46. Barker DE, Trepashko D, DeMarais P, et al. Utility of thallium brain SPECT in the exclusion of CNS lymphoma in AIDS. Abstract No. 708. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22–26, 1996.
47. Barlow KL, Tosswill JH, Clewley JP. Analysis and genotyping of PCR products of the Amplicor HIV-1 kit. *J Virol Methods.* 1995;52(1–2):65–74.
48. Barlow KL, Tosswill JH, Parry JV, Clewley JP. Performance of the Amplicor human immunodeficiency virus type 1 PCR and analysis of specimens with false-negative results. *J Clin Microbiol.* 1997;35:2846–2853.
49. Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in patients with human immunodeficiency virus infection. *N Engl J Med.* 1991;324:1644–1650
50. Barnes PF. Rapid diagnostic tests for tuberculosis: Progress but no gold standard. *Am J Respir Crit Care Med.* 1997;155:1497–1498
51. Baron AD, Hollander H. *Pseudomonas aeruginosa* bronchopulmonary infection in late human immunodeficiency virus disease. *Am Rev Respir Dis.* 1993;148:992–996.
52. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science.* 1983;220:868.

53. Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. *Ann Intern Med.* 1996;125:161–172.
54. Baumgartner J, Rachlin J, Beckstead J, et al. Primary central nervous system lymphomas: Natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. *J Neurosurg.* 1990;73:206–211.
55. Bayard-McNeeley M, Doo H, He S, et al. Differential effects of interleukin-12, interleukin-15, and interleukin-2 on human immunodeficiency virus type 1 replication in vitro. *Clin Diagn Lab Immunol.* 1996;3:547–553
56. Bayer R, Toomey KE. HIV prevention and the two faces of partner notification. *Am J Public Health.* 1992;82:1158–1164.
57. Beard CB, Navin TR. Molecular epidemiology of *Pneumocystis carinii* pneumonia (Commentary). *Emerg Infect Dis.* 1996;2:147.
58. Beauvergie L, Carbonnel F, Carrat F, et al. Factors of weight loss in patients with HIV and chronic diarrhea. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1998;19:34–39.
59. Behets, F., M. Kashamuka, and M. Pappaioanou et al. Stability of human immunodeficiency virus type 1 antibodies in whole blood dried on filter paper and stored under various tropical conditions in Kinshasa, Zaire. *J. Clin. Microbiol.* 1992; 30: 1179-1182.
60. Bender BS, Augor FA, Quinn TC, et al. Impaired antibody-dependent cell-mediated cytotoxic activity in patients with the acquired immunodeficiency syndrome. *Clin Exp Immunol.* 1986;64:166–172
61. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. *Hepatology* 1999;30:1302-6.
62. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin's lymphoma. *Lancet.* 1991;337:805.
63. Beral V, Peterman T, Berkelman R, Jaffe H. Kaposi's sarcoma among persons with AIDS: A sexually transmitted infection? *Lancet.* 1990;335:123–128.
64. Berberian L, Goodglick L, Kipps TJ, et al. Immunoglobulin V_H3 gene products: Natural ligands for HIV gp120. *Science.* 1993;261:1588–1591.
65. Berenguer J, Padilla B, Estrada V, Martin C, Domingo P, Kindelan JM, Ruiz-Guardin JM. Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. *AIDS.* 2002 Jun 14;16(9):1299-301.
66. Berger AR, Arezzo JC, Schaumburg HH, et al. 2',3'-Dideoxycytidine (ddC) toxic neuropathy: A study of 52 patients. *Neurology.* 1993;43:358–362.
67. Berger AR, Sheremata W, Resnick L, et al. Multiple sclerosis-like illness occurring with human immunodeficiency virus infection. *Neurology.* 1987;39:324–329.
68. Bernstein Z, Wilson D, Summers K, et al. Pilot/phase I study—Photodynamic therapy (PDT) for treatment of AIDS-associated Kaposi's sarcoma (AIDS/KS). *Proc Am Soc Clin Oncol.* 1995;14:289.
69. Berson J, Long D, Doranz B, et al. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. *J Virol.* 1996;70:6288–6295.
70. Biberfeld P, Chayt K, Marselle L, et al. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. *Am J Pathol.* 1986;125:436–442.
71. Biggar RJ, Rabkin CS. The epidemiology of AIDS-related neoplasms. *Hematol Oncol Clin North Am.* 1996;10:997–1010.
72. Biggs BA, Hewish M, Kent S, et al. HIV-1 infection of human macrophages impairs phagocytosis and killing of *Toxoplasma gondii*. *J Immunol.* 1995;154:6132–6139
73. Bisset LR, Cone RW, Huber W, et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. *AIDS.* 1998;12:2115–2123.
74. Bissuel F, Berruyer M, Causee X, et al. Acquired protein S deficiency: Correlation with advanced disease in HIV-1-infected patients. *J Acquir Immune Defic Syndr.* 1987;294:143–144.
75. Biti R, French R, Young J, et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. *Nat Med.* 1997;3:252–253
76. Blanche S, Rouzioux C, Moscato MLG, et al. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. *N Engl J Med.* 1989;320:1643–1648.
77. Blanco JL, Mallolas J, Sarasa M, Martinez E, Garcia-Viejo MA, Lonca M, Lozano L, Tuste M, Codina C, Carne X, Pumarola T, Gatell JM. A pilot study of a twice-daily (BID) combination of indinavir/delavirdine plus two nucleoside analogues for salvage therapy in HIV-1 infected patients. Abstract 1543. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2000; Toronto.
78. Blauvelt A, Katz SI. The skin as target, vector, and effector organ in human immunodeficiency virus disease. *J Invest Dermatol.* 1995;105(Suppl):122S–126S.
79. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature.* 1996;382:829–833.

80. Bloom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. *Ann Intern Med.* 1988;109:963–969
81. Blum AS, Dal Pan GJ, Feinberg J, et al. Low-dose zalcitabine–related toxic neuropathy: Frequency, natural history, and risk factors. *Neurology.* 1996;46:999–1003.
82. Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone vs. trimethoprim-sulfamethoxazole for primary prophylaxis of *Pneumocystis carinii* pneumonia. *J Acquir Immune Defic Syndr.* 1992;15:341–347.
83. Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone vs. trimethoprim-sulfamethoxazole for primary prophylaxis of *Pneumocystis carinii* pneumonia. *J Acquir Immune Defic Syndr.* 1992;15:341–347.
84. Boehringer Ingelheim Pharmaceuticals, Inc. Tipranavir Anti-Viral Drugs Advisory Committee (AVDAC) Briefing Document. April 19, 2005. Available at: www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4139b1-02-boehringer.pdf.
85. Boily MC, Anderson RM. Sexual contact patterns between men and women and the spread of HIV-1 in urban centres in Africa. *IMA J Math Appl Med Biol.* 1991;8:221–247.
86. Boldt-Houle DM, Rinaldo CR, Ehrlich GD. Random depletion of T cells that bear specific T cell receptor V beta sequences in AIDS patients. *J Leukoc Biol.* 1993;54:486–491
87. Bollinger RC Jr, Kline RL, Francis HL, et al. Acid dissociation increases the sensitivity of p24 antigen detection for the evaluation of antiviral therapy and disease progression in asymptomatic human immunodeficiency virus–infected persons. *J Infect Dis.* 1992;165:913–916.
88. Borkowsky W, Krasinski K, Paul D, et al. Human immunodeficiency virus type 1 antigenemia in children. *J Pediatr.* 1989;114:940–945.
89. Borkowsky W, Krasinski K, Pollack H, et al. Early diagnosis of human immunodeficiency virus infection in children <6 months of age: Comparison of polymerase chain reaction, culture, and plasma antigen capture techniques. *J Infect Dis.* 1992;166:616–619.
90. Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. *J Virol.* 1994;68:6103–6110.
91. Borthwick NJ, Bofill M, Gombert WM, et al. Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28- T cells. *AIDS.* 1994;8:431–441.
92. Bottles K, McPhaul LW, Volberding P. Fine-needle aspiration biopsy of patients with the acquired immunodeficiency syndrome (AIDS): Experience in an outpatient clinic. *Ann Intern Med.* 1988;108:42–45.
93. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. *Clin Infect Dis.* 2001;33(11):1931-7.
94. Boyce RA, Seña A, Cates W, Cohen MS. Sexual transmission of HIV. *N Engl J Med.* 1997;336:1072–1078
95. Boyer V, Smith LR, Ferre F, et al. T cell receptor V beta repertoire in HIV-infected individuals: Lack of evidence for selective V beta deletion. *Clin Exp Immunol.* 1993;92:437–441.
96. Boyle MJ, Berger MF, Tschuchnigg M, et al. Increased expression of interferon-gamma in hyperplastic lymph nodes from HIV-infected patients. *Clin Exp Immunol.* 1993;92:100–105.
97. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome. *N Engl J Med.* 1990;323:1451–1457.
98. Braaten D, Franke EK, Luban J. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. *J Virol.* 1996;70:3551.
99. Bradley WG, Verma A. Painful vasculitic neuropathy in HIV-1 infection: Relief of pain with prednisone therapy. *Neurology.* 1996;47:1446–1451.
100. Branson, B.M. Assessing Diagnostic Technologies Marketed to Less Industrialized Countries. *Journal of International Physicians in AIDS Care* 2000; 28-30.
101. Braun M. Classics in oncology. Idiopathic multiple pigmented sarcoma of the skin by Kaposi. *CA Cancer J Clin.* 1982;32:340–347
102. Bremer JW, Lew JF, Cooper E, et al. Diagnosis of infection with human immunodeficiency virus type 1 by a DNA polymerase chain reaction assay among infants enrolled in the Women and Infants' Transmission Study. *J Pediatr.* 1996;129(2):198–207.
103. Brenner M, Ognibene FP, Lack EE, et al. Prognostic factors and life expectancy of acquired immunodeficiency syndrome patients with *Pneumocystis carinii* pneumonia. *Am Rev Respir Dis.* 1987;136:1199–1206.
104. Broder CC, Berger EA. Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages. *Proc Natl Acad Sci U S A.* 1995;92:9004–9008
105. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. *AIDS.* 1997;11:1731–1738.

106. Browne MJ, Mayer KH, Chafee SB, et al. 2',3'-Didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase I trial. *J Infect Dis.* 1993;167:21–29.
107. Buchbinder S, Vittinghoff E, Colfax G, Holmberg S. Declines in AIDS incidence associated with highly active antiretroviral therapy (HAART) are not reflected in KS and lymphoma incidence. Abstract S7. Presented at the Second National AIDS Malignancy Conference, Bethesda, Md, April 6–8, 1998.
108. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. *J Infect Dis.* 1992;166:1153–1156.
109. Budka H. Neuropathology of human immunodeficiency virus infection. *Brain Pathol.* 1991;1:163–175.
110. Bukrinsky M, Stanwick T, Dempsey M, et al. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. *Science.* 1991;254:423–427.
111. Burgard M, Mayaux MJ, Blanche S, et al. The use of viral culture and p24 antigen testing to diagnose human immunodeficiency virus infection in neonates. *N Engl J Med.* 1992;327:1192–1197.
112. Burgard M, Mayaux MJ, Blanche S, et al. The use of viral culture and p24 antigen testing to diagnose human immunodeficiency virus infection in neonates. The HIV Infection in Newborns French Collaborative Study Group. *N Engl J Med.* 1992;327:1192–1197.
113. Burkes R, Meyer P, Gill P, et al. Rectal lymphoma in homosexual men. *Arch Intern Med.* 1986;146:913–915.
114. Bush CE, Donovan RM, Markowitz NP, et al. A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. *J Acquir Immun Defic Syndr Hum Retrovirol.* 1996;13:23–26.
115. Bylund DJ, Ziegner UH, Hooper DG. Review of testing for human immunodeficiency virus. *Clin Lab Med.* 1992;12:305–333.
116. Cahn P, et al. 24-week data from RESIST 2: phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimized ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV+ patients. In: Program and abstracts of the Seventh International Congress on Drug Therapy in HIV Infection; November 14-17, 2004; Glasgow, UK. Abstract PL14.3.
117. Calabresse LH, Proffitt MR, Levin KH, et al. Acute infection with the human immunodeficiency virus (HIV) associated with acute brachial neuritis and exanthematous rash. *Ann Intern Med.* 1987;107:849–851.
118. Caldwell P, Murphy R, Chan C. Atovaquone suspension for prophylaxis of *Pneumocystis carinii* pneumonia: Effects of baseline prophylaxis on safety and efficacy. Abstract No. 22178. In: Conference Records, 12th World AIDS Conference, Geneva, June 28, 1998.
119. Caliendo AM, Hirsch MS. Combination therapy for infection due to human immunodeficiency virus type 1 [published erratum appears in *Clin Infect Dis.* 1994;19:379]. *Clin Infect Dis.* 1994;18:516–524.
120. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. *Lancet.* 1998;351:543–549.
121. Cameron DW, Simonsen JN, D'Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: Risk factors for seroconversion in men. *Lancet.* 1989;2:403–407.
122. Campo RE, Campo CE. *Mycobacterium kansasii* disease in patients infected with human immunodeficiency virus. *Clin Infect Dis.* 1997;24:1233–1238
123. Cao J, Park IW, Cooper A, et al. Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1. *J Virol.* 1996;70:1340–1354.
124. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. *N Engl J Med.* 1995;332:201–208.
125. Cardo DM, Colver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health-care workers after percutaneous exposure. *N Engl J Med.* 1997;337:1485–1490.
126. Carey RF, Herman WA, Retta SM, et al. Effectiveness of latex condoms as a barrier to human immunodeficiency virus-sized particles under conditions of simulated use. *Sex Transm Dis.* 1992;19:230–234
127. Carne CA, Tedder RS, Smith A, et al. Acute encephalopathy coincident with seroconversion for anti-HTLV-III. *Lancet.* 1985;2:1206–1208.
128. Carne CA, Tedder RS, Smith A. Acute encephalopathy coincident with seroconversion for anti-HTLV-III. *Lancet.* 1985;2:1206–1208.
129. Carne CA, Weller IVD, Loveday C, et al. From persistent generalized lymphadenopathy to AIDS: Who will progress? *BMJ.* 1987;294:868–869.
130. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA panel. *JAMA.* 1998;280:78–86.
131. Carr A, Marriott D, Field A, et al. Treatment of HIV-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. *Lancet.* 1998;351:256.
132. Carr A, Swanson C, Penny R, Cooper DA. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with *Pneumocystis* pneumonia and AIDS. *Clin Infect Dis.* 1993;167:180–185.

133. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. *Ann Intern Med.* 1992;117:106–111.
134. Carvalho MB, Hamerschlag N, Vaz RS, Ferreira OC Jr. Risk factor analysis and serological diagnosis of HIV-1/HIV-2 infection in a Brazilian blood donor population: Validation of the World Health Organization strategy for HIV testing. *AIDS.* 1996;10:1135–1140.
135. Cassol S, Butcha A, Kinard S, et al. Rapid screening for early detection of mother-to-child transmission of human immunodeficiency virus type 1. *J Clin Microbiol.* 1994;32:2641–2645.
136. Cassol, S.A., S. Read, and B.G. Weniger et al.. Dried blood spots collected on filter paper: An international resource for the diagnosis and genetic characterization of human immunodeficiency virus type-1. *Mem Inst Oswaldo Cruz, Rio de Janeiro,* 1996; 91: 351-358.
137. Castellanos F, Mallada J, Ricart C, Zabala JA. Ataxic neuropathy associated with human immunodeficiency virus seroconversion. *Arch Neurol.* 1994;51:236.
138. Catanzaro AB, Davidson L, Fujiwara PI, et al. Proceedings of the American Thoracic Society Workshop, “Rapid diagnostic tests for tuberculosis. What is the appropriate use?” *Am J Respir Crit Care Med.* 1997;155:1804–1814.
139. Caumes E, Roudier C, Rogeaux O, et al. Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole during treatment of AIDS-associated *Pneumocystis carinii* pneumonia. *Clin Infect Dis.* 1994;18:319–323.
140. CDC (Centers for Disease Control). Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. *MMWR Morb Mortal Wkly Rep.* 1989;38(S-7):1–7.
141. Cello JP, Grendell JH, Basuk P, et al. Effect of octreotide on refractory AIDS-associated diarrhea. *Ann Intern Med.* 1991;115:705.
142. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 1997;9:39.
143. Centers for Disease Control and Prevention. Human immunodeficiency virus infection in the United States: A review of current knowledge. *MMWR Morb Mortal Wkly Rep.* 1987;36(Suppl 6):S1–S48.
144. Centers for Disease Control and Prevention. Kaposi's sarcoma and *Pneumocystis pneumonia* among homosexual men—New York City and California. *MMWR Morb Mortal Wkly Rep.* 1981 (b);30:305–308.
145. Centers for Disease Control and Prevention. *Pneumocystis pneumonia*—Los Angeles. *MMWR Morb Mortal Wkly Rep.* 1981 (a);30:250–252.
146. Centers for Disease Control and Prevention. Prevention and Treatment of Tuberculosis Among Patients Infected with Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. *MMWR Morb Mortal Wkly Rep.* 1998;47(RR-20):1–58.
147. Centers for Disease Control and Prevention. Update: Trends in AIDS incidence, death, and prevalence—United States, 1996. *MMWR Morb Mortal Wkly Rep.* 1997a;46:165–173.
148. Centers for Disease Control and Prevention. Update: Trends in AIDS incidence—United States, 1996. *MMWR Morb Mort Wkly Rep.* 1997b;46:861–867.
149. Centers for Disease Control and Prevention: Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. *MMWR Morb Mortal Wkly Rep.* 1990;39(RR-1):1–14.
150. Centers for Disease Control and Prevention: Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. *MMWR Morb Mortal Wkly Rep.* 1998;47(RR-7):1–33.
151. Centers for Disease Control and Prevention: Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. *MMWR Morb Mortal Wkly Rep.* 1986;35:231–233.
152. Centers for Disease Control and Prevention: Update: Barrier protection against HIV infection and other sexually transmitted diseases. *MMWR Morb Mortal Wkly Rep.* 1993;42:589–591.
153. Centers for Disease Control and Prevention: Update: Investigations of patients who have been treated by HIV-infected healthcare workers—United States. *MMWR Morb Mortal Wkly Rep.* 1993;42:329–337.
154. Centers for Disease Control. Revision of the Case Definition of AIDS Used by CDC for National Reporting (CDC Reportable AIDS), 1985. Atlanta: Department of Health and Human Services; 1985.
155. Chaisson RE, Bacchetti P, Osmond D, et al. Cocaine use and HIV infection in intravenous drug users in San Francisco. *JAMA.* 1989;261:561–565
156. Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. *AIDS.* 1998;12:29–33.
157. Chaisson RE, Keruly J, Richman DD, et al. *Pneumocystis* prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. *Arch Intern Med.* 1992;152:2009–2013.
158. Chak L, Gill P, Levine A, et al. Radiation therapy for AIDS-related Kaposi's sarcoma. *J Clin Oncol.* 1988;6:863–867.
159. Chamberland ME, Bell DM. HIV transmission from health care worker to patient: What is the risk (Editorial). *Ann Intern Med.* 1992;116:871–873.

160. Chamberland ME, Conley LJ, Bush TJ, et al. Health care workers with AIDS. National surveillance update. *JAMA*. 1991;266:3459–3462.
161. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science*. 1994;266:1865–1869.
162. Chant K, Lowe D, Rubin G, et al. Patient-to-patient transmission of HIV in private surgical consulting rooms (Letter). *Lancet*. 1993;342:1548–1549
163. Chariot P, Ruet E, Authier FJ, et al. Acute rhabdomyolysis in patients infected by human immunodeficiency virus. *Neurology*. 1994;44:1692–1696.
164. Chaturvedi S, Newman SL. Modulation of the effector function of human macrophages for *Histoplasma capsulatum* by HIV-1. Role of the envelope glycoprotein gp120. *J Clin Invest*. 1997;100:1465–1474.
165. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: Initial single-rising-dose study in humans. *Antimicrob Agents Chemother*. 1993;37:178–182.
166. Chen CH, Weinhold KJ, Bartlett JA, et al. CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: A novel antiviral mechanism. *AIDS Res Hum Retroviruses*. 1993;9:1079–1086.
167. Chen MS, Dellabeta G, Laga M, Holmes KK. A new deal in HIV prevention: Lessons from the global approach. *Ann Intern Med*. 1994;120:340–341.
168. Cheng-Mayer C, Liu R, Landau NR, et al. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. *J Virol*. 1997;71:1657–1661
169. Chiodi F, Albert J, Olausson E. Isolation frequency of human immunodeficiency virus from cerebrospinal fluid and blood of patients with varying severity of HIV infection. *AIDS Res Hum Retroviruses*. 1988;4:351–358.
170. Chiodi F, Albert J, Olausson E. Isolation frequency of human immunodeficiency virus from cerebrospinal fluid and blood of patients with varying severity of HIV infection. *AIDS Res Hum Retroviruses*. 1988;4:351–358.
171. Choe H, Farzan M, Sun Y, et al. The β -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. *Cell*. 1996;85:1135–1138
172. Choremi-Papadopoulou H, Viglis V, Gargalianos P, et al. Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV-1 infection. *J Acquir Immune Defic Syndr*. 1994;7:245–253.
173. Chun T-W, Engel D, Ehler L, et al. Induction of HIV-1 replication in latently infected CD4(+) T cells using a combination of cytokines. *J Exp Med*. 1998;188:83–91.
174. Ciesielski C, Marianos D, Ou CY, et al. Transmission of human immunodeficiency virus in a dental practice. *Ann Intern Med*. 1992;116:798–805
175. Cingolani A, De Luca A, Ammassari A, et al. PCR detection of *Toxoplasma gondii* DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. *J Med Microbiol*. 1996;45:472
176. Ciricillo S, Rosenblum M. Use of CT and MRI imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. *J Neurosurg*. 1990;73:720–724.
177. Ciricillo S, Rosenblum M. Use of CT and MRI imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. *J Neurosurg*. 1990;73:720–724.
178. Clark SJ, Kelen GD, Henrard DR, et al. Unsuspected primary human immunodeficiency virus type 1 infection in seronegative emergency department patients. *J Infect Dis* 1994; 170:194–197.
179. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. *N Engl J Med*. 1991;324:954–960.
180. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. *N Engl J Med*. 1991;324:954–960.
181. Clarke S, Mulcahy F, Back D, Gibbons S, Tjia J, Barry M. Managing methadone and non-nucleoside reverse transcriptase inhibitors: guidelines for clinical practice. Abstract 88. 7th Conference on Retroviruses and Opportunistic Infections. January 30 - February 2, 2000; San Francisco.
182. Claydon EJ, Bennett J, Gor D, et al. Transient elevation of serum HIV antigen levels associated with intercurrent infection (Letter). *AIDS*. 1991;5:113–114.
183. Cleary PD, Fowler FJ, Weissman J, et al. Health-related quality of life in persons with acquired immune deficiency syndrome. *Med Care*. 1993;31:569–580.
184. Clements GJ, Price-Jones MJ, Stephens PE, et al. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: A possible function in viral fusion? *AIDS Res Hum Retroviruses*. 1991;7:3–16.
185. Clendeninn N, Quart B, Anderson R, et al. Analysis of long-term virologic data from the VIRACEPT (nelfinavir, NFV) 511 protocol using 3 HIV-RNA assays. Abstract 372. In: 5th Conference on Retroviruses and Opportunistic Infections. Chicago; 1998:148.
186. Clerici M, Balotta C, Meroni L, et al. Type 1 cytokine production and low prevalence of viral isolation correlate with long term non-progression in HIV infection. *AIDS Res Hum Retroviruses*. 1996;12:1053–1061

187. Clerici M, Hakim F, Venzon D, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. *J Clin Invest.* 1993;91:759–765.
188. Clerici M, Lucey DR, Zajac RA, et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. *J Immunol.* 1991;146:2214–2219.
189. Clerici M, Shearer G. A TH1-TH2 switch is a critical step in the etiology of HIV infection. *Immunol Today.* 1993;14:107–111
190. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients independent of CD4+ cell numbers and clinical settings. *J Clin Invest.* 1989;84:1892–1899
191. Clerici M, Wynn T, Berzofsky J, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. *J Clin Invest.* 1994;93:768–775.
192. Clumeck N, Taelman H, Hermans P, et al. A cluster of HIV infection among heterosexual people without apparent risk factors. *N Engl J Med.* 1989;321:1460–1462.
193. Cocchi F, DeVico A, Garzino-Demo A, et al. Identification of RANTES, MIP-1 α , and MIP-1 β as the major HIV suppressive factors produced by CD8+ T cells. *Science.* 1995;270:1811–1815.
194. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. *Science.* 1995;267:483–489.
195. Cohen CR, Duerr A, Pruthithada N, et al. Bacterial vaginosis and HIV seroprevalence among female commercial sex workers in Chaing Mai, Thailand. *AIDS.* 1995;9:1093–1097.
196. Cohen MS. Sexually transmitted diseases enhance HIV transmission: No longer a hypothesis. *Lancet.* 1998;351:(Suppl 3):S5–S7.
197. Cohen O, Kinter A, Fauci A. Host factors in the pathogenesis of HIV infection. *Immunol Rev.* 1997;159:31–48.
198. Cohen O, Vaccarezza M, Lam G, et al. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long term non-progressors. *J Clin Invest.* 1997;100:1581–1589.
199. Cohen PR, Beltrani VP, Grossman ME. Disseminated herpes zoster in patients with human immunodeficiency virus infection. *Am J Med.* 1988;84:1076–1080.
200. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. *Ann Intern Med.* 1993;119:786–793.
201. Collier AC, Meyers JD, Corey L, et al. Cytomegalovirus infection in homosexual men: Relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. *Am J Med.* 1987;23:593.
202. Collins KL, Chen BK, Kalams SA, et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. *Nature.* 1998;391: 397–401.
203. Collman R, Hassan NF, Walker R, et al. Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. *J Exp Med.* 1989;170:1149–1163.
204. Colonna R, Parkin N, McLaren C, Seekins D, Hodder S, Schnittman S, and Kelleher T. Pathways to Atazanavir Resistance in Treatment-experienced Patients and Impact of Residue 50 Substitutions. 11th Conference on Retrovirus and Opportunistic Infections, San Francisco, February 8-11, 2004. Abstract 656.
205. Colonna R, Rose R, Cianci C, Aldrovandi G, Parkin N, Friborg J. Emergence of Atazanavir Resistance and Maintenance of Susceptibility to Other PIs is Associated with an I50L Substitution in HIV Protease. 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 9-14, 2003. Abstract 597.
206. Colonna RJ, Thiry A, Limoli K, Parkin N. Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors. *Antimicrob Agents Chemother.* 2003 Apr;47(4):1324-33.
207. Combadiere C, Ahuja SK, Tiffany HL, et al. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. *J Leukoc Biol.* 1996;60:147–152
208. Conley AJ, Kessler JA, Boots LJ, et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. *Proc Natl Acad Sci U S A.* 1994;91:3348–3352.
209. Connolly KJ, Hammer SM. Antiretroviral therapy: Reverse transcriptase inhibition. *Antimicrob Agents Chemother.* 1992;36:245–254
210. Connor RI, Mohri H, Cao Y, et al. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. *J Virol.* 1993;67:1772–1777.

211. Conte JE, Chernoff D, Feigal DW, et al. Intravenous or inhaled pentamidine for treating *Pneumocystis carinii* pneumonia in AIDS. *Ann Intern Med.* 1990;113:203–209.
212. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced HIV infection. *J Infect Dis.* 1996;174:705–712.
213. Cooper D, Hicks C, Cahn P, et al. 24-Week RESIST Study Analyses: the Efficacy of Tipranavir/Ritonavir Is Superior to Lopinavir/Ritonavir, and the TPV/r Treatment Response is Enhanced by Inclusion of Genotypically Active Antiretrovirals in the Optimized Background Regimen. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston. Abstract 560.
214. Cooper DA, Gold J, Maclean P, et al. Acute AIDS retrovirus infection: Definition of a clinical illness associated with seroconversion. *Lancet.* 1985;1:537–540.
215. Cooper DA, Imrie AA, Penny R. Antibody response to human immunodeficiency virus after primary infection. *J Infect Dis.* 1987;155:1113–1118.
216. Copeland KF, McKay PJ, Rosenthal KL. Suppression of activation of the human immunodeficiency virus long terminal repeat by CD8+ T cells is not lentivirus specific. *AIDS Res Hum Retroviruses.* 1995;11:1321–1326.
217. Corbett AH, Davidson L, Park JJ, Patterson K, Eron JJ, Ngo L, Lim ML, Shelton M, Wire MB, and Kashuba ADM. Dose Separation Strategies to Overcome the Pharmacokinetic Interaction of a Triple Protease Inhibitor Regimen Containing Fosamprenavir Lopinavir, and Ritonavir. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004. Abstract 611.
218. Cox S, Bonway B, Freimuth W, Berber E, Paxton L, Carel B, Nieto L, Rivera C, Wolff M, Benetucci J, Cahn P, Williams K. Pilot Study of BID and TID combinations of saquinavir-SGC, delavirdine, zidovudine, and lamivudine as initial therapy: pharmacokinetic interaction between S-SGC and D. Abstract 82. 7th Conference on Retroviruses and Opportunistic Infections. January 30 - February 2, 2000; San Francisco.
219. Crowe SM, Vardaxis NJ, Kent SJ, et al. HIV infection of monocyte-derived macrophages in vitro reduces phagocytosis of *Candida albicans*. *J Leukoc Biol.* 1994;56:318–327.
220. Cuadrado LM, Guerrero A, Asenjo LG, et al. Cerebral mucormycosis in two cases of the acquired immunodeficiency syndrome. *Arch Neurol.* 1988;45:109–111.
221. Cuevas MT, Ruibal I, Villahermosa ML, et al. High HIV-1 genetic diversity in Cuba. *AIDS 2002*, in press.
222. Cunningham CK, Britto P, Gelber R, et al. Genotype resistance analysis in women participating in PACTG 316 with HIV-1 RNA >400 copies/ml. Abstract 712, 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, USA.
223. Cupler EJ, Dalakas MC. Exacerbation of peripheral neuropathy by lamivudine. *Lancet.* 1995;345:460–461.
224. Curran JW, Lawrence DN, Jaffe H, et al. Acquired immunodeficiency syndrome (AIDS) associated with transfusions. *N Engl J Med.* 1984;310:69–75.
225. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. *N Engl J Med.* 1991;324:961–964.
226. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. *N Engl J Med.* 1990;322:1098–1105.
227. Daley CL, Small PM, Schechter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency virus: An analysis using restriction-fragment-length polymorphisms. *N Engl J Med.* 1992;326:231–235.
228. Dalglish AG, Beverly PC, Clapham PR, et al. The CD4(T4) antigen is an essential component of the receptor for the AIDS retrovirus. *Nature.* 1984;312:763–767
229. Dallabetta GA, Miotti PG, Chiphangui JD, et al. High socio-economic status is a risk factor for human immunodeficiency virus type 1 (HIV-1) infection but not for sexually transmitted diseases in women in Malawi: Implications for HIV-1 control. *J Infect Dis.* 1993;167:36–42
230. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfonamides. *Ann Intern Med.* 1992; 116:33–43.
231. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. *N Engl J Med.* 1995;333:1528–1533.
232. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. *Ann Intern Med.* 1996;124:1019–1030.

233. Davey RT Jr, Chaitt DG, Reed GF, et al. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. *Antimicrob Agents Chemother.* 1996;40:1657–1664.
234. Davey RT Jr, Deyton LR, Metcalf JA, et al. Indeterminate Western blot patterns in a cohort of individuals at high risk for human immunodeficiency virus (HIV-1) exposure. *J Clin Immunol.* 1992;12(3):185–192.
235. Davis LE, Hjelle BL, Miller VE. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. *Neurology.* 1992;42:1736–1739.
236. Davis LE, Hjelle BL, Miller VE. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. *Neurology.* 1992;42:1736–1739.
237. Davis S, Henschke C, Chamides B, Westcott J. Intrathoracic Kaposi sarcoma in AIDS patients: Radiographic-pathologic correlation. *Radiology.* 1987;163:495–500.
238. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. *Clin Microbiol Rev.* 1995;8:200–239.
239. de Gans J, Portegies P, Reiss P, et al. Pyrimethamine as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. *J Acquir Immune Defic Syndr.* 1992;5:137–142.
240. De Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. *N Engl J Med.* 1994;331:341–346
241. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. *Science.* 1995;270:988–991.
242. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the *CCR5* structural gene. *Science.* 1996;273:1856–1862.
243. Dear Health Care Provider Letter from GlaxoSmithKline, "Early Virologic Non-Response I Patients with HIV Infection Treated with Lamivudine, Abacavir and Tenofovir." July 25, 2003.
244. Dear Health Care Provider, Re: Reyataz (atazanavir sulfate) With or Without Norvir (ritonavir) and Proton Pump Inhibitors Should Not Be Coadministered: Important New Pharmacokinetic Data. Bristol-Myers Squibb. December 2004.
245. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. *JAMA.* 1997;277:145–153.
246. Defer C, Agut H, Gabarg-Chenon A, et al. Multicentre quality control of polymerase chain reaction for detection of HIV DNA. *AIDS.* 1992;6:659–663.
247. DeJarlais D, Marmor M, Thomas P, et al. Kaposi's sarcoma among four different AIDS risk groups. *Lancet.* 1988;1:1119.
248. DeJesus E, Grinsztejn B, Rodriguez C, Nieto-Cisneros L, Coco J, Lazzarin A, Lichtenstein K, Johnson M, Rightmire A, Sanko S, and Wilber R. Efficacy and Safety of Atazanavir with Ritonavir or Saquinavir vs Lopinavir/Ritonavir in Patients Who Have Experienced Virologic Failure on Multiple HAART Regimens: 48-Week Results from BMS A1424-045. 11th Conference on Retrovirus and Opportunistic Infections, San Francisco, February 8-11, 2004. Abstract 547.
249. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER, Scott TR; CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. *Clin Infect Dis.* 2004 Oct 1;39(7):1038-46.
250. DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P. The Context Study: Efficacy and Safety of GW433908/RTV in PI-experienced Subjects with Virological Failure (24 Week Results). 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003. Abstract 178.
251. DeJesus, G. Herrera, E. Teofilo, S. Castillo, T. Bonny, D. Thorpe, J. Hernandez, T. Scott. Efficacy and Safety of Abacavir (ABC) Versus Zidovudine (ZDV) in Antiretroviral Therapy-Naive Adults With HIV-1 Infection (Study CNA30024). Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Illinois. Abstract H-446.
252. Delgado E, Thomson MM, Villahermosa ML, et al. Identification, by analysis of near full-length sequences, of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, exhibiting a pseudotype-like virion structure. *J Acquir Immune Defic Syndr* 2002; 29: 536-43.
253. Delta Coordinating Committee and Delta Virology Committee. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: An extended virology study. *AIDS.* 1999;13:57–65.
254. Delta Coordinating Committee. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. *Lancet.* 1996;348:283–291.
255. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee [published erratum appears in *Lancet.* 1996;348:834]. *Lancet.* 1996;348:283–291.

256. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. *Nature*. 1996;381:661–666
257. Denning DW, Anderson J, Rudge P, et al. Acute myelopathy associated with primary infection with human immunodeficiency virus. *BMJ*. 1987;294:143–144.
258. Denning DW, Anderson J, Rudge P, Smith H. Acute myelopathy associated with primary infection with human immunodeficiency virus. *BMJ*. 1987;294:143–144.
259. DeRossi A, Franchini G, Aldovini A, et al. Differential response to the cytopathic effects of human T-cell lymphotropic virus type III (HTLV-III) superinfection in T4+ (helper) and T8+ (suppressor) T-cell clones transformed by HTLV-1. *Proc Natl Acad Sci U S A*. 1986;83:4297–4301.
260. Derouin F, Piketty C, Chastang C, et al. Antitoxoplasma effects of dapsone alone and combined with pyrimethamine. *Antimicrob Agents Chemother*. 1991;35:252–255.
261. Des Jarlais D, Stoneburner R, Thomas P. Declines in proportion of Kaposi's sarcoma among cases of AIDS in multiple risk groups in New York City. *Lancet*. 1987;2:1024–1025.
262. Des Jarlais DC, Friedman SR, Novick DM, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. *JAMA*. 1989;261:1008–1012.
263. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vezinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team) *JAMA* 2000;283:205-11.
264. deWit R, Schatenkerk J, Boucher C, et al. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. *Lancet*. 1988;2:1214–1217.
265. Dezutter-Dambuyant C, Schmitt D. Epidermal Langerhans cells and HIV-1 infection. *Immunol Lett*. 1993;39:33–37.
266. Di Marzio P, Tse J, Landau NR. Chemokine receptor regulation and HIV type 1 tropism in monocytemacrophages. *AIDS Res Hum Retroviruses*. 1998;14: 129–138.
267. Diesenhause MC, Wilson LA, Corrent GF, et al. Treatment of microsporidial keratoconjunctivitis with topical fumagillin. *Am J Ophthalmol*. 1993;115:293.
268. Dieterich DT, Lew EA, Kotler DP, et al. Treatment with albendazole for intestinal disease due to *Enterocytozoon bieneusi* in patients with AIDS. *J Infect Dis*. 1994;169:178.
269. Dittmar MT, Simmons G, Hibbitts S, et al. Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups. *J Virol*. 1997;71:8008–8013
270. Dobrescu D, Kabak S, Mehta K, et al. Human immunodeficiency virus 1 reservoir in CD4+ T cells is restricted to certain V beta subsets. *Proc Natl Acad Sci U S A*. 1995;92:5563–5567.
271. Dobrescu D, Ursea B, Pope M, et al. Enhanced HIV-1 replication in V beta 12 T cells due to human cytomegalovirus in monocytes: Evidence for a putative herpesvirus superantigen. *Cell*. 1995;82:753–763
272. Dobs AS, Dempsey MA, Ladenson PW, et al. Endocrine disorders in men infected with human immunodeficiency virus. *Am J Med*. 1988;84:611–616.
273. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for *Pneumocystis carinii* pneumonia in patients with AIDS. *Ann Intern Med*. 1994;121:174–180.
274. Dolin R, Amato DA, Fischl MA, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group [published erratum appears in *Arch Intern Med*. 1995;155:2255]. *Arch Intern Med*. 1995;155:961–974.
275. Donegan E, Stuart M, Niland JC, et al. Infection with human immunodeficiency virus type 1 (HIV1) among recipients of antibody-positive blood donations. *Ann Intern Med*. 1990;113:733–739.
276. Donovan RM, Bush CE, Markowitz NP, et al. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus–infected persons. *J Infect Dis*. 1996;174:401–403.
277. Doranz B, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the α -chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. *Cell*. 1996;85:1149–1158
278. Dore GJ, Marriott DJ, Hing MC, et al. Disseminated microsporidiosis due to *Septata intestinalis* in nine patients infected with the human immunodeficiency virus: Response to therapy with albendazole. *Clin Infect Dis*. 1995;21:70.
279. Dorenbaum A. for the PACTG 316 Study Team. Report of results of PACTG 316: An international phase III trial of standard antiretroviral (ARV) prophylaxis plus nevirapine (NVP) for prevention of perinatal HIV transmission. Abstract LB7, 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, USA.
280. Dorfman R. Kaposi's sarcoma revisited. *Hum Pathol*. 1984;15:1013–1017.
281. Douglas GC, King BF. Maternal-fetal transmission of human immunodeficiency virus: A review of possible routes and cellular mechanisms of infection. *Clin Infect Dis*. 1992;15:678–691.
282. Dragic T, Litwin V, Allaway G, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. *Nature*. 1996;381:667–673

283. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD; MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. *J Infect Dis.* 2003 Sep 1;188(5):635-42.
284. Drew WL, Miner RC, Ziegler JL, et al. Cytomegalovirus and Kaposi's sarcoma in young homosexual men. *Lancet.* 1982;1:125.
285. Dropulic LK, Leslie JM, Eldred LJ, et al. Clinical manifestations and risk factors of *Pseudomonas aeruginosa* infection in patients with AIDS. *J Infect Dis.* 1995;171:930-937.
286. Dube MP, Holtom PD, Larsen RA. Tuberculous meningitis in patients with and without human immunodeficiency virus infection. *Am J Med.* 1992;93:520-524.
287. Duh EJ, Maury WJ, Folks TM, et al. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. *Proc Natl Acad Sci U S A.* 1989;86:5974-5978
288. Dunn DT, Newell ML, Ades AE, et al. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. *Lancet.* 1992;340:585-588.
289. Durack DT. Opportunistic infections and Kaposi's sarcoma in homosexual men. *N Engl J Med.* 1981;305:1465.
290. Eberstadt, N. The Future of AIDS. *Foreign Affairs*, November/December 2002
291. Ehrnst A, Lindgren S, Dictor M, et al. HIV in pregnant women and their offspring: Evidence for late transmission. *Lancet.* 1991;338:203-207.
292. el Sadr WM, Simberkoff MS. Survival and prognostic factors in severe *Pneumocystis carinii* pneumonia requiring mechanical ventilation. *Am Rev Respir Dis.* 1988;137:1264-1267.
293. Elder G, Dalakas M, Pezeshkpour G, et al. Ataxic neuropathy due to ganglioneuritis after probable acute human immunodeficiency virus infection. *Lancet.* 1986;2:1275-1276.
294. Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. *Arch Neurol.* 1997;54:416-424.
295. El-Sadr W, Luskin-Hawk R, Pulling C, et al. Daily versus thrice weekly trimethoprim-sulfamethoxazole in the prevention of *P. carinii* pneumonia (CPCRA 006). Abstract I-146. In: Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, September 13-16, 1997.
296. El-Sadr W, Murphy R, Luskin-Hawk R, et al. Atovaquone vs. dapsone in the prevention of *P. carinii* pneumonia in patients intolerant to trimethoprim and/or sulfamethoxazole. Abstract No. 769. In: Abstracts of the 35th Annual Meeting of the Infectious Disease Society of America, San Francisco, September 13-16, 1997.
297. Embretson J, Zupancic M, Ribas J, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. *Nature*;1993;362:359-362.
298. Emilie D, Peuchmaur M, Maillot MC, et al. Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. *J Clin Invest.* 1990;86: 148-159.
299. Emmons W. Accuracy of oral specimen testing for human immunodeficiency virus. *Am J Med.* 1997;102(4A):15-20.
300. Emmons WW, Paparello SF, Dreker CF, et al. A modified ELISA and Western blot accurately determine anti-human immunodeficiency virus type 1 antibodies in oral fluids obtained with a special collecting device. *J Infect Dis.* 1995;171:1406-1410.
301. Emtriva package insert. Gilead Sciences, July 2003.
302. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. *JAMA.* 1996;275:1329-1334.
303. Ennen J, Seipp I, Norley SG, et al. Decreased accessory cell function of macrophages after infection with human immunodeficiency virus type 1 in vitro. *Eur J Immunol.* 1990;20:2451-2456.
304. Eron J, Haubrich R, Richman D, et al. Preliminary assessment of 141W94 in combination with other protease inhibitors. Abstract 6. In: 5th Conference on Retroviruses and Opportunistic Infections. Chicago; 1998:80.
305. Eron JJ Jr, Johnson VA, Merrill DP, et al. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. *Antimicrob Agents Chemother.* 1992;36:1559-1562.
306. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. *N Engl J Med.* 1995;333:1662-1669.
307. Eron JJ, Vernazza PL, Johnston DM, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: Implications for transmission. *AIDS.* 1998;12:F181-F189.
308. Esser R, vonBriesen H, Brugger M, et al. Secretory repertoire of HIV-infected human monocytes/macrophages. *Pathobiology.* 1991;59:219-222
309. Esteves A, Parreira R, Venenno T, et al. Molecular epidemiology of HIV type 1 infection in Portugal: high prevalence of non-B subtypes. *AIDS Res Hum Retroviruses* 2002; 18: 313-25.

310. Eugen-Olsen J, Iversen AKN, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS free survival and slower CD4 T cell fall in a cohort of HIV seropositive individuals. *AIDS*. 1997;11:305–310.
311. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. *Lancet*. 1992;339:1007–1012.
312. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. *BMJ*. 1992;304:809–813.
313. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. *BMJ*. 1992;304:809–813.
314. Evatt BL, Ramsey RB, Lawrence DN, et al. The acquired immunodeficiency syndrome in patients with hemophilia. *Ann Intern Med*. 1984;100:499–504
315. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. *N Engl J Med*. 1990;322:166–172.
316. Farthing C, Khanlou H, Yeh V. Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Abacavir, Lamivudine and Tenofovir in the Treatment Naive HIV-Infected Patients. The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 2003. Abstract 43.
317. Farthing C, Khanlou H, Yeh V. Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Abacavir, Lamivudine and Tenofovir in the Treatment-Naive HIV-Infected Patients The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris. July 13-16, 2003. Abstract 43.
318. Farthing C, Khanlou H, Yeh V. Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Abacavir, Lamivudine and Tenofovir in the Treatment-Naive HIV-Infected Patients The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Abstract 43.
319. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. *Lancet*. 1998;352:1510–1514.
320. Farzadegan H, Polis MA, Wolinsky SM, et al. Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men. A report from the Multicenter AIDS Cohort Study. *Ann Intern Med*. 1988;108:785–790.
321. Farzadegan H, Taylor E, Hardy W, et al. Performance of serological assays for early detection of human immunodeficiency virus type 1 seroconversion. *J Clin Microbiol*. 1989;27:1882–1884.
322. Fauci A. Host factors and the pathogenesis of HIV-induced disease. *Nature*. 1996;384:529–534.
323. Fauci, A., H.C. Lane. 2000. Human immunodeficiency virus (HIV) disease: AIDS and related disorders. In *Harrison's Principles of Internal Medicine*, 14th Edition (CD-ROM version). New York: McGraw-Hill.
324. Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: Three San Francisco epidemiological cohorts. *AIDS*. 1991;5:519–525.
325. Feng Y, Broder C, Kennedy P, et al. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane domain, G-protein coupled receptor. *Science*. 1996;272:872–877
326. Fernandez R, Mouradian J, Metroka C, et al. The prognostic value of histopathology in persistent generalized lymphadenopathy in homosexual men. *N Engl J Med*. 1983;309:185–186.
327. Fernandez-Martin J, Lepout C, Morlat P, et al. Pyrimethamine-clarithromycin combination for therapy of acute *Toxoplasma encephalitis* in patients with AIDS. *Antimicrob Agents Chemother*. 1991;35:2049.
328. Ferrari G, Kostyu DD, Cox J, Dawson DV, Flores J, Weinhold KJ, et al. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in *Mycobacterium bovis* BCG-vectored vaccines. *AIDS Res Hum Retroviruses* 2000; 16: 1433-43.
329. Fichtenbaum CJ, Woeltje KF, Powderly WG. Serious *Pseudomonas aeruginosa* infections in patients infected with human immunodeficiency virus: A case-control study. *Clin Infect Dis*. 1994;19:417–422.
330. Finkel TH, Tudor-Williams G, Banda NK, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. *Nat Med*. 1995;1:129–134.
331. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science*. 1997;278:1295–1300.
332. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for *Pneumocystis carinii* pneumonia in AIDS. *JAMA*. 1988;259:1185–1189.
333. Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. *Ann Intern Med*. 1993;118:762–769.
334. Fischl MA, Richman DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. *JAMA*. 1989;262:2405–2410

335. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. *N Engl J Med*. 1987;317:185–191.
336. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. *N Engl J Med* 1987;317:185-91.
337. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. *Ann Intern Med*. 1990;112:727–737.
338. Fisher M, Stoehr A, Podzamczar D, et al. A randomized double-blind study of d4T + ddI vs ZDV + ddI as initial treatment in subjects with CD4 count less than or equal to 500 cells/mm. Abstract 661. In: 5th Conference on Retroviruses and Opportunistic Infections. Chicago; 1998:204.
339. Fisher, J.D., and Fisher, W.A. Changing AIDS risk behavior. *Psychol Bull*, 1992; 111: 455-474.
340. Flexner C. HIV-protease inhibitors. *N Engl J Med*. 1998;338:1281–1292.
341. Floridia M, Buccioni R, Ricciardulli D, et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naïve patients with advanced disease. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1992;20:11–19.
342. Formenti S, Gill P, Rarick M, et al. Primary central nervous system lymphoma in AIDS: Results of radiation therapy. *Cancer*. 1989;63:1101–1107.
343. Forsyth PA, Yahalom J, DeAngelis LM. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. *Neurology*. 1994;44:1473–1479.
344. Fortes, P., J. Menitove, and A. Ross et al. 1989. Evaluation of blood collected on filter paper for detection of antibodies to human immunodeficiency virus type 1. *J. Clin Microbiol* 27: 1380-1381.
345. Fox R, Eldred LJ, Fuchs EJ, et al. Clinical manifestations of acute infection with human immunodeficiency virus in a cohort of gay men. *AIDS*. 1987;1:35–38.
346. Freed EO, Myers DJ, Riser R. Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. *J Virol*. 1991;65:190–194.
347. Frerichs, R.R., M.T. Htoon, N. Eskes, and S. Lwin. Comparison of saliva and serum for HIV surveillance in developing countries. *The Lancet*; 1992; 340:1496-1499.
348. Friedman-Kien A, Laubenstein LJ, Rubinstein P, et al. Disseminated Kaposi's sarcoma in homosexual men. *Ann Intern Med*. 1982;96:693–700.
349. Friedman-Kien AE, Lafleur FL, Gendler E, et al. Herpes zoster: A possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals. *J Am Acad Dermatol*. 1986;14:1023–1028.
350. Frizzera G, Rosai J, Dehner L, et al. Lymphoreticular disorders in primary immunodeficiencies: New findings based on an up-to-date histologic classification of 35 cases. *Cancer*. 1980;46:692–699.
351. Fuller GN, Jacobs JM, Guiloff RJ. Nature and incidence of peripheral nerve syndrome in HIV infection. *J Neurol Neurosurg Psychiatry*. 1993;56:372–381
352. Fultz PN, Gluckman JC, Muchmore E, et al. Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. *AIDS Res Hum Retroviruses*. 1992;8:313–317.
353. Furci L, Scarlatti G, Burastero S, et al. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. *J Exp Med*. 1997;186:455–460.
354. Gabiano C, Tovo PA, de Martino M, et al. Mother-to-child transmission of human immunodeficiency virus type 1: Risk of infection and correlates of transmission. *Pediatrics*. 1992;90:369–374.
355. Gabuzda DH, Hirsch MS. Neurologic manifestations of infection with human immunodeficiency virus: Clinical features and pathogenesis. *Ann Intern Med*. 1987;107:383–391.
356. Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome—a double-blind, placebo-controlled trial. *N Engl J Med*. 1990; 323:1444–1450.
357. Gaines H, Non Sydow M, Sonnerborg A, et al. Antibody response in primary human immunodeficiency virus infection. *Lancet*. 1987;2:1249–1253.
358. Gallant J, Staszewski S, Pozniak A, Lu B, Miller MD, Coakley DF, and Cheng A. Favorable Lipid and Mitochondrial (mt) DNA Profile for Tenofovir Disoproxil Fumarate (TDF) Compared to Stavudine (d4T) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral Therapy (ART) Naïve Patients: A 48 Week Interim Analysis. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract LB-2.
359. Gallant JE, Rodriguez AE, Weinberg W, Young B, Berger D, Lim ML, Liao Q, Ross L, Johnson J, Shafer MS. Early Non-Response to Tenofovir DF (TDF) + Abacavir (ABC) and Lamivudine (3TC) in a Randomized Trial Compared to Efavirenz (EFV) + ABC and 3TC: ESS30009. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 2003. Abstract 1722a.

360. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. *JAMA*. 2004 Jul 14;292(2):191-201.
361. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. *JAMA*. 2004 Jul 14;292(2):191-201.
362. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. *JAMA*. 2004 Jul 14;292(2):191-201.
363. Gallo D, George JR, Fitchen JH, et al. Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing. OraSure HIV Clinical Trials Group. *JAMA*. 1997;277:254-258.
364. Gallo R, Salahuddin S, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. *Science*. 1984;224:500-503.
365. Gallo RC, Montagnier L. AIDS in 1988. *Sci Am*. 1988;259:41.
366. Gallo RC, Montagnier L. The Discovery of HIV as the Cause of AIDS. *N. Engl. J Med*. 2003; 349:2283-2285
367. Gallo RC, Salahuddin SZ, Popovic M, et al. Human T-lymphotropic retrovirus, HTLV-III, isolated from AIDS patients and donors at risk for AIDS. *Science*. 1984;224:500
368. Gallo RC. Virus hunting. New York: Basic Books, 1991.
369. Gao F, Balles E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee *Pan troglodytes troglodytes*. *Nature* 1999; 397: 436-41
370. Gao WY, Shirasaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. *J Clin Invest*. 1993;91:2326-2333.
371. Garcia S, Dadaglio G, Cilote V, et al. Evidence for an in vivo superantigenic activity in human immunodeficiency virus-infected individuals. *Blood*. 1996;88:2151-2161
372. Gerberding J. Provider-to-patient HIV transmission: How to keep it exceedingly rare. *Ann Intern Med*. 1999;130:1-6
373. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and cytomegalovirus among health care personnel at risk for blood exposure: Final report from a longitudinal study. *J Infect Dis*. 1994;170:1410-1417.
374. Ghiodi F, Asjo B, Fanyo EM, et al. Isolation of HIV from cerebrospinal fluid of antibody-positive virus carrier without neurological symptoms. *Lancet*. 1986;2:1276-1277.
375. Ghiodi F, Asjo B, Fanyo EM, et al. Isolation of HIV from cerebrospinal fluid of antibody-positive virus carrier without neurological symptoms. *Lancet*. 1986;2:1276-1277.
376. Giannetti A, Zambruno G, Cimarelli A, et al. Direct detection of HIV-1 RNA in epidermal Langerhans cells of HIV-infected patients. *J Acquir Immune Defic Syndr*. 1993;6:329-333
377. Gibson, David R., "Effectiveness of Syringe Exchange Programs in Reducing HIV Behavior and HIV Seroconversion Among Injecting Drug Users," *AIDS*, 2001.
378. Giles R., K. Perry, and J. Parry. Simple/Rapid test devices for anti-HIV screening: Do they come up to the mark? *J Med Virol*. 1999;59:104-109.
379. Gill MJ. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team. *AIDS*. 1998;12:1400-1402.
380. Gill P, Akil B, Colletti P, et al. Pulmonary Kaposi's sarcoma: Clinical findings and results of therapy. *Am J Med*. 1989;87:57-61.
381. Gill P, Hadenberg J, Espina B, et al. Low dose paclitaxel (Taxol) every two weeks over 3 hours is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. Abstract 1516. Presented at the American Society of Hematology (ASH), Thirty-ninth Annual Meeting, Seattle, December 2-5, 1995.
382. Gill P, Levine A, Meyer R, et al. Primary central nervous system lymphoma in homosexual men: Clinical, immunologic and pathologic factors. *Am J Med*. 1985;78:742-748.
383. Gill P, Wernz J, Scadden D, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. *J Clin Oncol*. 1996;14:2353-2364.
384. Ginaldi L, De Martinis M, D'Ostilio A, et al. Changes in antigen expression on B lymphocytes during HIV infection. *Pathobiology*. 1998;66:17-23.
385. Giorgi JV, Ho H-N, Hirji K, et al. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: Development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. *J Infect Dis*. 1994;170:775-781.
386. Girard P-M, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against *Pneumocystis carinii* pneumonia and toxoplasmosis in HIV infection. *N Engl J Med*. 1993;328:1514-1520.

387. Girard P-M, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against *Pneumocystis carinii* pneumonia and toxoplasmosis in HIV infection. *N Engl J Med*. 1993;328:1514–1520.
388. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. *Antimicrob Agents Chemother*. 2002 Jun;46(6):1734-40.
389. Glaser JB, Morton-Kute L, Berger SR, et al. Recurrent *Salmonella typhimurium* bacteremia associated with the acquired immunodeficiency syndrome. *Ann Intern Med*. 1985;102:189–193.
390. Glesby MJ, Moore RD, Chaisson RE. Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. *J Infect Dis*. 1993;168:1264–1268.
391. Goedert JJ, Biggar RJ, Melbye M, et al. Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. *JAMA*. 1987;257:331–334.
392. Goedert JJ, Duliege AM, Amos CI, et al. High risk of HIV-1 infection for firstborn twins. *Lancet*. 1991;338:1471–1475.
393. Goedert JJ, Eyster ME, Bigger RJ, et al. Heterosexual transmission of human immunodeficiency virus: Association with severe depletion of T-helper lymphocytes in men with hemophilia. *AIDS Res Hum Retroviruses*. 1987;3:355–361.
394. Golden JA, Katz MH, Chernoff DN, et al. A randomized comparison of once monthly or twice monthly high dose aerosolized pentamidine prophylaxis. *Chest*. 1993;104:743–750.
395. Golding H, Shearer G, Hillman K, et al. Common epitope in human immunodeficiency virus (HIV)1 gp41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV 1–infected individuals. *J Clin Invest*. 1989;83:1430–1435
396. Goldstein J, Dickson D, Moser F, et al. Primary central nervous system lymphoma in acquired immunodeficiency syndrome: A clinical and pathologic study with results of treatment with radiation. *Cancer*. 1991;67:2756.
397. Goletti D, Weissman D, Jackson RW, et al. Effect of *Mycobacterium tuberculosis* on HIV replication. Role of immune activation. *J Immunol*. 1996;157:1271–1278.
398. Golletti D, Weissman D, Jackson RW, et al. Effect of *Mycobacterium tuberculosis* on HIV replication. Role of immune activation. *J Immunol*. 1996; 157:1271–1278.
399. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, et al. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. *Proc Natl Acad Sci USA*. 1998;95:14938–14943.
400. Gonzalez-Scarano F, Kolson DL, Albright AV. Viral receptors and cellular mechanisms of HIV-2 entry into the central nervous system. In: Gendelman HE, Lipton SA, Epstein L, Swindells S, eds. *Neurology of AIDS*. New York: Chapman & Hall; 1998:36–48.
401. Gonzalez-Scarano F, Kolson DL, Albright AV. Viral receptors and cellular mechanisms of HIV-2 entry into the central nervous system. In: Gendelman HE, Lipton SA, Epstein L, Swindells S, eds. *Neurology of AIDS*. New York: Chapman & Hall; 1998:36–48.
402. Goodglick L, Zevit N, Neshat MS, et al. Mapping the Ig superantigen–binding site of HIV-1 gp120. *J Immunol*. 1995;155:5151–5159.
403. Gordin FM, Cohn DL, Sullam PM, et al. Early manifestations of disseminated *Mycobacterium avium* complex disease: A prospective evaluation. *J Infect Dis*. 1997;176:126.
404. Gordin FM, Simon GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. *Ann Intern Med*. 1984;100:495–499.
405. Gotch FM, Nixon DF, Alp N, et al. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. *Int Immunol*. 1990;2:707–712.
406. Goto Y, Yeh CK, Notkins AL, et al. Detection of proviral sequences in saliva of patients infected with human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses*. 1991;7:343–347.
407. Gottlieb MS, Schroff R, Schanker HM, et al. *Pneumocystis carinii* pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. *N Engl J Med*. 1981;305:1425
408. Goudsmit J, De Wolf F, Paul DA, et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. *Lancet*. 1986;2:177–180.
409. Goudsmit J, de Wolf F, Paul DA. Expression of human immunodeficiency virus antigen (HIV-ag) in serum and cerebrospinal fluid during acute and chronic infection. *Lancet*. 1986;2:177–180.
410. Goudsmit J, de Wolf F, Paul DA. Expression of human immunodeficiency virus antigen (HIV-ag) in serum and cerebrospinal fluid during acute and chronic infection. *Lancet*. 1986;2:177–180.
411. Goudsmit J, Debouck C, Melen RH, et al. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. *Proc Natl Acad Sci U S A*. 1988;85:4478–4482.
412. Gougeon M-L, Lecoœur H, Dulioust A, et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons. *J Immunol*. 1996;156:3509–3520.

413. Graham NM, Zeger SL, Park LP, et al. Effect of zidovudine and *Pneumocystis carinii* pneumonia prophylaxis on progression of HIV-1 infection to AIDS. *Lancet*. 1991;338:265–269.
414. Graham NM, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. *N Engl J Med*. 1992;326:1037–1042.
415. Granelli-Piperno A, Moser B, Pope M, et al. Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. *J Exp Med*. 1996; 184:2433–2438.
416. Grant I, Gold J, Armstrong D. Risk of CNS toxoplasmosis in patients with acquired immune deficiency syndrome. Abstract 441. Program of the Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 28–October 1, 1986.
417. Grassi F, Meneveri R, Gullberg M, et al. Human immunodeficiency virus type 1 gp120 mimics a hidden monomorphic epitope borne by class I major histocompatibility complex heavy chains. *J Exp Med*. 1991;174:53–62
418. Grassly NC, Garnett GP, Schwartzlander B, Gregson S, Anderson RM. The effectiveness of HIV prevention and the epidemiological context. *Bull World Health Organ* 2001; 79: 1121-32.
419. Graziosi C, Gantt K, Vaccarezza M, et al. Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. *Proc Natl Acad Sci U S A*. 1996;93:4386–4391.
420. Graziosi C, Pantaleo G, Gantt KR, et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. *Science*. 1994;265: 248–252.
421. Green TL, Beckstead JH, Lozada-Nur F, et al. Histopathologic spectrum of oral Kaposi's sarcoma. *Oral Surg Oral Med Oral Pathol*. 1984;58:306–314.
422. Greenblatt R, et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. *AIDS*. 1988;2:47.
423. Greenblatt RM, Lukehart SA, Plummer FA, et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. *AIDS*. 1988;2:47–50
424. Greenough TC, Brettler DB, Somasundaran M, et al. Human immunodeficiency virus type 1–specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: Evidence supporting a protective role for CTL in vivo. *J Infect Dis*. 1997;176:118–125
425. Greenspan D, Greenspan JS, Conant M, et al. Oral “hairy” leukoplakia in male homosexuals: Evidence of association with both papillomavirus and a herpes-group virus. *Lancet*. 1984;2:831–834.
426. Greenspan D, Greenspan JS, Hearst NG, et al. Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and risk of developing AIDS. *J Infect Dis*. 1987;155:475–481.
427. Greenspan JS, Greenspan D, Lennette ET, et al. Replication of Epstein-Barr virus within the epithelial cells of oral “hairy” leukoplakia and AIDS-associated lesion. *N Engl J Med*. 1985;313:1564–1571.
428. Groopman J, Gottlieb M, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. *Ann Intern Med*. 1984;100:671–676.
429. Grossman MC, Grossman ME. Chronic hyperkeratotic herpes zoster and human immunodeficiency virus infection. *J Am Acad Dermatol*. 1993;28:306–308.
430. Groux H, Torpier G, Monte D, et al. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus–infected asymptomatic individuals. *J Exp Med*. 1992;175:331–340
431. Grube H, Ramratnam B, Ley C, et al. Resolution of AIDS associated cryptosporidiosis after treatment with indinavir. *Am J Gastroenterol*. 1997;92:726.
432. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. *N Engl J Med*. 1992 327:329–337.
433. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. *Lancet* 1999;354:795-802.
434. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. *MMWR Morb Mortal Wkly Rep*. 1998;47:43–82.
435. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini EA, Chodakewitz JA, Isaacs R, Richman DD. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. *Ann Intern Med* 2000;133:35-9.
436. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. *N Engl J Med*. 1997;337:734–739.
437. Gulick RM, Ribaldo HJ, Shikuma CM, Lustgarten S, Meyer WA, Klingman K, Squires KE, Snyder S, Kuritzkes, DR. ACTG 5095: A Comparative Study of Three Protease Inhibitor-Sparing Antiretroviral Regimens for the Initial Treatment of HIV Infection. The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13-16, 2003. Abstract 41.

438. Gulick RM, Ribaldo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. *N Engl J Med.* 2004 Apr 29;350(18):1850-61.
439. Gulick RM, Smeaton LM, D'Aquila RT, Eron JJ, Currier JS, Gerber JG, Acosta E, Sommadossi JP, Tung R, Snyder S, Kuritzkes DR, Murphy RL. Indinavir, Nevirapine, Stavudine, and Lamivudine for Human Immunodeficiency Virus-Infected, Amprenavir-Experienced Subjects: AIDS Clinical Trials Group Protocol 373. *J Infect Dis* 2001;183:715-721.
440. Gurtler L. Difficulties and strategies of HIV diagnosis. *Lancet.* 1996;348:176-179.
441. Guydish JR, Abramowitz A, Woods W, et al. Changes in needle sharing behavior among intravenous drug users: San Francisco, 1986-88. *Am J Public Health.* 1990;80:995-997.
442. Haase AT, Schacker TW. Potential for transmission of HIV-1 despite highly active antiretroviral therapy. *N Engl J Med.* 1998;339:1846-1848
443. Hagberg L, Maimvail B, Svennerholm B, et al. Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. *Scand J Infect Dis.* 1986;18:591-592.
444. Hammer S, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. *N Engl J Med.* 1996;335:1081-1090.
445. Hammer S, Squires K, Degruittola V, Fischl M, Bassett R, Demeter L, Hertogs K, Larder B. Randomized trial of abacavir (ABC) and nelfinavir (NFV) in combination with efavirenz (EFV) and adefovir dipivoxil (ADV) as salvage therapy in patients with virologic failure receiving indinavir (IDV). Abstract 490. 6th Conference on Retroviruses and Opportunistic Infections. Jan 31-Feb 4, 1999; Chicago.
446. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. *N Engl J Med.* 1996;335:1081-1090.
447. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. *N Engl J Med.* 1997;337:725-733.
448. Hammond SA, Obah E, Stanhope P, et al. Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. *J Immunol.* 1991;146:1470-1477.
449. Hanenberg RS, Rojanapithayakoron W, Kunasol P, Sokal DC. Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases. *Lancet.* 1994;344:243-245
450. Hanke T, McMichael M. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. *Nature Med* 2000; 6: 951-55.
451. Hanna, G., Hirsch, M.S. Antiretroviral Therapy of Human Immunodeficiency Virus Infection. In Mandell, Douglas and Bennett's principle and practice of infectious diseases. CD-ROM Edition, 2001.
452. Hanto D, Gajl-Peczalkska K, Frizzera G, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. *Cancer Res.* 1981;41:4253-4261.
453. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of *Pneumocystis carinii* pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group protocol 021. *N Engl J Med.* 1992;327:1842-1848.
454. Harris JE. Improved short-term survival of AIDS patients initially diagnosed with *Pneumocystis carinii* pneumonia, 1984 through 1987. *JAMA.* 1990;263:397-405.
455. Harwood A, Osoba D, Hofstader S, et al. Kaposi's sarcoma in recipients of renal transplants. *Am J Med.* 1979;67:759-765.
456. Harwood A, Osoba D, Hofstader S, et al. Kaposi's sarcoma in recipients of renal transplants. *Am J Med.* 1979;67:759-765.
457. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. *J Infect Dis.* 1995;171:537-545.
458. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. *J Virol.* 1996;70:7894-7899.
459. Havlir DV, Friedland G, Pollard R, et al. Combination zidovudine (ZDV) and stavudine (d4T) therapy versus other nucleosides: Report of two randomized trials (ACTG 290 and 298). Abstract 2. In: 5th Conference on Retroviruses and Opportunistic Infections. Chicago; 1998:79.
460. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. *JAMA* 2000;283:229-34.

461. Havlir DV, Tierney C, Friedland GH, Pollard RB, Smeaton L, Sommadossi JP, Fox L, Kessler H, Fife KH, Richman DD. In vivo antagonism with zidovudine plus stavudine combination therapy. *J Infect Dis* 2000;182:321-5.
462. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. *Nature*. 1997;385:645-649.
463. Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV 1) associated with clinical exposures. A prospective evaluation. *Ann Intern Med*. 1990;113:740-746.
464. Hendrix CW, Fiske WD, Fuchs EJ, Redpath EC, Stevenson DL, Benedek IH, Kornhauser DM. Pharmacokinetics of the Triple Combination of Saquinavir, Ritonavir, and Efavirenz in HIV-Positive Patients. Abstract 79. 7th Conference on Retroviruses and Opportunistic Infections. January 30 - February 2, 2000; San Francisco.
465. Hénin Y, Mandelbrot L, Henrion R, et al. Virus excretion in the cervical secretions of pregnant and nonpregnant HIV-infected women. *J Acquir Immune Defic Syndr*. 1993;6:72-75.
466. Henrard DR, Phillips J, Windsor I, et al. Detection of human immunodeficiency virus type 1 p24 antigen and plasma RNA: Relevance to indeterminate serologic tests. *Transfusion* 1994 34:376-380.
467. Hersh BS, Popovici F, Apetrei RC, et al. Acquired immunodeficiency syndrome in Romania. *Lancet*. 1991;338:645-649
468. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. *Lancet*. 2002 Mar 30;359(9312):1121-2.
469. Hicks C, et al. RESIST-1: A Phase 3 Randomized, Controlled, Open-Label Multicenter Trial Comparing Tipranavir/Ritonavir (TPV/r) to an Optimized Comparator Protease Inhibitor/r (CPI/r) Regimen in Antiretroviral (ARV) Experienced Patients: 24-Week Data. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 31-November 2, 2004; Washington. Abstract 1137a.
470. Hicks C, Hass D, Seekins D, et al. A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of DMP 266 (efavirenz, SUSTIVA) in combination with open-label zidovudine (ZDV) with lamivudine (3TC) [DMP 266-005]. Abstract 698. In: 5th Conference on Retroviruses and Opportunistic Infections. Chicago; 1998:209.
471. Hildreth JE, Orentas RJ. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. *Science*. 1989;244:1075-1078.
472. Hill D. The role of radiotherapy for epidemic Kaposi's sarcoma. *Semin Oncol*. 1987;14(Suppl 3):1207.
473. Hirschel B, Lazzarin A, Chopard P, et al. A controlled study of inhaled pentamidine for primary prevention of *Pneumocystis carinii* pneumonia. *N Engl J Med*. 1991;324:1079-1083.
474. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. *N Engl J Med*. 1995;333:845-851.
475. HIV Sequence Database. Los Alamos National Laboratory NM. <http://hiv-web.lanl.gov> .
476. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. *N Engl J Med*. 1989;321:1621-162
477. Ho DD, Rota TR, Schooley RT. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurological syndromes related to the acquired immunodeficiency syndrome. *N Engl J Med*. 1985;313:1493-1497.
478. Ho DD, Rota TR, Schooley RT. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurological syndromes related to the acquired immunodeficiency syndrome. *N Engl J Med*. 1985;313:1493-1497.
479. Ho DD, Sarngadharan MG, Resnick L, et al. Primary human T-lymphotropic virus type II infection. *Ann Intern Med*. 1985;103:880-883.
480. Ho DD, Sarngadharan MG, Resnick L, et al. Primary human T-lymphotropic virus type III infection. *Ann Intern Med*. 1985;103:880-883.
481. Ho DD. HIV-1 viraemia and influenza. *Lancet*. 1992;339:1549.
482. Hocqueloux L, Lesprit P, Herrmann J-L, et al. Pulmonary *Mycobacterium avium* complex disease without dissemination in HIV-infected patients. *Chest*. 1998;113:542-548.
483. Hoelscher M, Kim B, Maboko L, Mhalu F, von Sonnenburg F, Birx DL, McCutchan FE. High proportion of unrelated HIV-1 intersubtype recombinants in the Mbeya region of southwest Tanzania. *AIDS* 2001; 15: 1461-70.
484. Hoffenbach A, Langlade-Demoyen P, Dadaglio G, et al. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. *J Immunol*. 1989;142: 452-462.
485. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. *Lancet*. 1997;349:1294.
486. Hollander H, Levy JA. Neurologic abnormalities and recovery of human immunodeficiency virus from cerebrospinal fluid. *Ann Intern Med*. 1987;106:692-695.

487. Hollander H, Levy JA. Neurologic abnormalities and recovery of human immunodeficiency virus from cerebrospinal fluid. *Ann Intern Med.* 1987;106:692–695.
488. Hollander H, Stringari S. Human immunodeficiency virus–associated meningitis: Clinical course and correlations. *Am J Med.* 1987;83:813–816.
489. Holmberg SD, Stewart JA, Gerber AR, et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. *JAMA.* 1988;259:1048–1050.
490. Holtgrave, D.R., Qualls, N.L., Curran, J.W., et al. An overview of the effectiveness and efficiency of HIV prevention programs. *Public Health Reports,* 1994; 110: 134.
491. Holtzer C, Coleman R, Flaherty J. Cross-reactivity and patient outcomes in HIV-infected patients switched from TMP/SMZ to dapsone due to hypersensitivity reactions during PCP prophylaxis. Abstract No. 292. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, American Society of Microbiology, Washington, DC; January 22–26, 1997.
492. Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994–1997. *AIDS.* 1998;12:1931–1933.
493. Holtzman DM, Kaku DA, So YT. New-onset seizures associated with human immunodeficiency virus infection: Causation and clinical features in 100 cases. *Am J Med.* 1989;87:173–177.
494. Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. *J Virol.* 1990;64:1437–1440.
495. Honda Y, Rogers L, Nakata K, et al. Type I interferon induces inhibitory 16-kD CCAAT/enhancer binding protein (C/EBP) beta, repressing the HIV-1 long terminal repeat in macrophages: Pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication. *J Exp Med.* 1998;188:1255
496. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. *Hepatology* 2000;32:635-9.
497. Hook E, et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. *J Infect Dis.* 1992;165:251.
498. Hoover R, Fraumeni J. Risk of cancer in renal transplant recipients. *Lancet.* 1973;2:55–57.
499. Horsburgh CR Jr, Ou CY, Jason J, et al. Duration of human immunodeficiency virus infection before detection of antibody. *Lancet.* 1989;2:637–640.
500. Hosmalin A, Clerici M, Houghten R, et al. An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. *Proc Natl Acad Sci U S A.* 1990;87:2344–2348.
501. Howcroft T, Strebel K, Martin M, et al. Repression of MHC class I gene promoter activity by two-exon tat of HIV. *Science.* 1993;260:1320–1322.
502. Hsia K, Tsai V, Zvaifler NJ, et al. Low prevalence of HIV-1 proviral DNA in peripheral blood monocytes and dendritic cells from HIV-1–infected individuals. *AIDS.* 1995;9:398–399.
503. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. *Science.* 1993;260:547–549
504. Hu DJ, Heyward WL, Byers RH Jr, et al. HIV infection and breastfeeding: Policy implications through a decision analysis model. *AIDS.* 1992;6:1505–1513.
505. Hu PF, Hultin LE, Hultin P, et al. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1995;10:331–340.
506. Huang Y, Paxton W, Wolinsky S, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. *Nat Med.* 1996;2:1240–1243.
507. Huang Y, Zhang L, Ho D. Biological characterization of nef in long term survivors of human immunodeficiency virus type 1 infection. *J Virol.* 1995;69:8142–8146.
508. Huang Y, Zhang L, Ho DD. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. *J Virol.* 1995;69:93–100.
509. Humphrey RW, O'Brien TR, Newcomb FM, et al. Kaposi's sarcoma (KS)–associated herpesvirus-like KNA sequences in peripheral blood mononuclear cells: Association with KS and persistence in patients receiving anti-herpesvirus drugs. *Blood.* 1996;88:297–301.
510. Hutto C, Parks WP, Lai S, et al. A hospital-based prospective study of perinatal infection with human immunodeficiency virus type 1. *J Pediatr.* 1991;118:347–353.
511. Imberti L, Sottini A, Bettinardi A, et al. Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences. *Science.* 1991;254: 860–862.
512. Ioachim HL, Lerner CW, Tapper ML. The lymphoid lesions associated with the acquired immunodeficiency syndrome. *Am J Surg Pathol.* 1983;7:543–553.
513. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian multicenter study. *Arch Intern Med.* 1993;153:1451–1458.
514. Irwin, K., N. Olivo, and C.A. Schable et al. 1996. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. *Ann Intern Med* 125:471-475.

515. Israelski DM, Chmiel JS, Poggenser L, et al. Prevalence of *Toxoplasma* infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. *J Acquir Immune Defic Syndr*. 1993;6:414–418.
516. Iversen AKN, Shpaer EG, Rodrigo AG, et al. Persistence of attenuated rev genes in a human immunodeficiency virus type 1–infected asymptomatic individual. *J Virol*. 1995;69:5743–5753.
517. Jackson JB, Drew J, Lin HJ, et al. Establishment of a quality assurance program for human immunodeficiency virus type 1 DNA polymerase chain reaction assays by the AIDS Clinical Trials Group, ACTG PCR Working Group, and the ACTG PCR Virology Laboratories. *J Clin Microbiol*. 1993;31:3123–3128.
518. Jackson JB, Mracna M, Guay L, et al. Selection of Nevirapine (NVP) resistance mutations in Ugandan women and infants receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET-012). Abstract LbOr 13, 13th International AIDS Conference 2000, Durban, South Africa.
519. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. *N Engl J Med*. 1997;336:1487–1493.
520. Jacobson L. Impact of highly effective antiretroviral therapy on recent trends in cancer among HIV-infected individuals. Abstract S5. Presented at the Second National AIDS Malignancy Conference, Bethesda, Md, April 6–8, 1998.
521. Jacobson MA. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. *N Engl J Med*. 1997;337:105
522. Jaffe HW, Hardy AM, Morgan WM, et al. The acquired immunodeficiency syndrome in gay men. *Ann Intern Med*. 1985;103:662–664.
523. Janoff EN, Breiman RF, Daley CL, et al. Pneumococcal disease during HIV infection. *Ann Intern Med*. 1992;117:314–324.
524. Janoff NE, Breiman RF, Daley CL, et al. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. *Ann Intern Med*. 1992;117:314–324.
525. Janossy G, Pinching AJ, Bofill M, et al. An immunohistological approach to persistent lymphadenopathy and its relevance to AIDS. *Clin Exp Immunol*. 1985;59:257–266.
526. Jarvik JG, Hesselink JR, Kennedy C, et al. Acquired immunodeficiency syndrome: Magnetic resonance patterns of brain involvement with pathologic correlation. *Arch Neurol*. 1998;45:731–736.
527. Javaherian K, Langlois AJ, McDanal C, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. *Proc Natl Acad Sci U S A*. 1989;86:6768–6772.
528. Jemsek J, Hutcherson P, and Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco. February 8-11, 2004. Abstract 51.
529. Jemsek J, Hutcherson P, Harper E. Poor Virologic Responses and Early Emergence of Resistance in Treatment Naive, HIV-infected Patients Receiving a Once Daily Triple Nucleoside Regimen of Didanosine, Lamivudine, and Tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 51.
530. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment-naive, HIV-infected patients receiving a once-daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections; San Francisco; February 8-11, 2004. Abstract 51.
531. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, Johnson KA. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. *J Biol Chem* 2001; 276:40847-57.
532. Johnson AM, Petherick A, Davidson SJ, et al. Transmission of HIV to heterosexual partners of infected men and women. *AIDS*. 1989;3:367–372.
533. Johnson AM. Condoms and HIV transmission. *N Engl J Med*. 1994;331:391–392
534. Johnson VA, Merrill DP, Chou TC, Hirsch MS. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. *J Infect Dis*. 1992;166:1143–1146.
535. Johnson VA, Merrill DP, Videler JA, et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. *J Infect Dis*. 1991;164:646–655.
536. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. *AIDS*, 2002. 16(18):2447-54.
537. Jones BD, Taikwel EK, Mercado AL, et al. Tuberculosis in patients with HIV infection who receive corticosteroids for presumed *Pneumocystis carinii* pneumonia. *Am J Respir Crit Care Med*. 1994;149:1686–1688.
538. Jones J, Hanson D, Ward J. Effect of antiretroviral therapy on recent trends in cancer among HIV-infected persons. Abstract S3. Presented at the Second National AIDS Malignancy Conference, Bethesda, Md, April 6–8, 1998.

539. Jost S, Bernard MC, Kaiser L, et al. HIV super-infection: rapid replacement of AE subtype by B subtype. 9th Conference on Retroviruses and Opportunistic Infections; Washington; 24–28 February, 2002.
540. Jourdain G, Ngo-Giang-Huong N, Tungyai P, et al. Exposure to Intrapartum Single-dose Nevirapine and Subsequent Maternal 6-Month Response to NNRTI-based Regimens. Abstract 41LB. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, February 8-11, 2004.)
541. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. *N Engl J Med.* 1992;327:581–587.
542. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. *N Engl J Med.* 1998;339:33
543. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. *N Engl J Med* 1998;339:33–39.
544. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. *Clin Ther* 2000;22:685-708.
545. Kalayjian RC, Toossi Z, Tomashefski JF Jr, et al. Pulmonary disease due to infection by *Mycobacterium avium* complex in patients with AIDS. *Clin Infect Dis.* 1995;20:1186–1194.
546. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, et al. A new subtype of human T-cell leukaemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukaemia. *Science.* 1982;218:571
547. Kamenga M, Ryder RW, Jingu M, et al. Evidence of marked sexual behaviour change associated with low HIV-1 seroconversion in 149 married couples with discordant HIV-1 status: Experiences at an HIV counselling centre in The Democratic Republic of Congo. *AIDS* 1991;5:61–67.
548. Kane, B. Rapid testing for HIV: Why so fast? *Ann Internal Med.* 1999; 131: 481-483.
549. Kapiga SH, Shao JF, Lwihula GK, et al. Risk factors for HIV infection among women in Dar-es-Salaam, Tanzania. *J Acquir Immune Defic Syndr.* 1994;7:301–309.
550. Kaplan JE, Hanson D, Jones J. Risk factors for primary PCP in HIV-infected adolescents and adults in the U.S. Should history of AIDS-defining illness be included in the criteria for PCP prophylaxis? Abstract 290. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, American Society of Microbiology, Washington, DC; January 22–26, 1997.
551. Kaplan JE, Hanson D, Jones J. Risk factors for primary PCP in HIV-infected adolescents and adults in the U.S. Should history of AIDS-defining illness be included in the criteria for PCP prophylaxis? Abstract 290. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, American Society of Microbiology, Washington, DC; January 22–26, 1997.
552. Kaplan L, Hopewell P, Jaffe H. Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome. *J Acquir Immune Defic Syndr.* 1988;1:23–30.
553. Kaplan L, Kahn J, Jacobson M, et al. Primary bile duct lymphoma in the acquired immunodeficiency syndrome (AIDS). *Ann Intern Med.* 1989;110:162.
554. Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. *JAMA.* 1989;261:719–724
555. Kaposi M. Zur Nomenclatur des idiopathischen Pigmentsarkom Kaposi. *Arch Dermatol Syph (Berl)* 1894;29:164.
556. Karhumaki E, Viljanen ME, Cottler-Fox M, et al. An improved enrichment method for functionally competent, highly purified peripheral blood dendritic cells and its application to HIV-infected blood samples. *Clin Exp Immunol.* 1993;91:482–488.
557. Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR, Collier AC. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. *AIDS.* 2005 Jan 28;19(2):145-52.
558. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. *Nat Med.* 1996;2:405–411.
559. Kassler WJ, Haley C, Jones WK, et al. Performance of a rapid, on-site human immunodeficiency virus antibody assay in a public health setting. *J Clin Microbiol.* 1995;33:2899–2902.
560. Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. *Clin Infect Dis.* 1996;22:268
561. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. *JAMA.* 1996;276:118–125.
562. Katlama C, Valantin MA, Matheron S, et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection. *Ann Intern Med.* 1998;129:525–531.

563. Kawakami K, Scheiderei C, Roeder RG. Identification and purification of a human immunoglobulin enhancer-binding protein (NF- κ B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. *Proc Natl Acad Sci U S A*. 1988;85:4700.
564. Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. 10th Conference on Retroviruses and Opportunistic Infections, Seattle, February 9-14, 2002. Abstract 533.
565. Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. 10th Conference on Retroviruses and Opportunistic Infections; February 9-14, 2002; Seattle. Abstract 533.
566. Kedes DH, Operskalski E, Busch M, et al. The epidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission. *Nat Med*. 1996;2:918-924.
567. Keet IP, Klein MR, Just JJ, et al. The role of host genetics in the natural history of HIV-1 infection: The needles in the haystack. *AIDS*. 1996;10(Suppl A): S59-S67.
568. Kehrl JH, Rieckmann P, Kozlow E, et al. Lymphokine production by B cells from normal and HIV-infected individuals. *Ann N Y Acad Sci*. 1992;651:220-227.
569. Kelly, J.A., Murphy, D.A., Sikkema, K.J., and Kalichman, S.C. Psychological interventions to prevent HIV infection are urgently needed: new priorities for behavioral research in the second decade of AIDS. *Am. Psychol* 1993; 48: 1023-1034.
570. Kemper CA, Tucker RM, Lang DS, et al. Low dose dapsone prophylaxis of *Pneumocystis carinii* pneumonia in AIDS and AIDS-related complex. *AIDS*. 1990;4:1145-1148.
571. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. *Proc Natl Acad Sci U S A*. 1995;92:2484-2488.
572. Kennedy CA, Goetz MB. Atypical roentgenographic manifestations of *Pneumocystis carinii* pneumonia. *Arch Intern Med*. 1992;152:1390-1398
573. Kent SJ, Stent G, Sonza S, et al. HIV-1 infection of monocyte-derived macrophages reduces Fc and complement receptor expression. *Clin Exp Immunol*. 1994;95: 450-454.
574. Kerkau T, Bacik I, Bennink JR, et al. The human immunodeficiency virus type 1 (HIV-1) vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. *J Exp Med*. 1997;185:1295-1305.
575. Kessler HA, Blaauw B, Spear J, et al. Diagnosis of human immunodeficiency virus infection in seronegative homosexuals presenting with an acute viral syndrome. *JAMA*. 1987;258:1196-1199.
576. Khadir A, Coutlee F, Saint-Antoine P, et al. Clinical evaluation of Amplicor HIV-1 test for detection of human immunodeficiency virus type 1 proviral DNA in peripheral blood mononuclear cells. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1995;9(3):257-263.
577. Kido H, Fukutomi A, Katunuma N. A novel membrane-bound serine esterase in human T4+ lymphocytes immunologically reactive with antibody inhibiting syncytia induced by HIV-1. Purification and characterization. *J Biol Chem*. 1990;265:21979-21985.
578. Kiebertz K, Yiannoutsos CP, Simpson D, AIDS Clinical Trials Group. A double-blind, randomized clinical trial of amitriptyline and mexiletine for painful neuropathy in human immunodeficiency virus infection (Abstract). *Ann Neurol*. 1997;42:429.
579. Kiebertz KD, Eskin TA, Ketonen L, Tuite MJ. Opportunistic cerebral vasculopathy and stroke in patients with the acquired immunodeficiency syndrome. *Arch Neurol*. 1993;50:430-432.
580. Kiebertz KD, Seidlin M, Lambert JS, et al. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. *J Acquir Immune Defic Syndr*. 1992;5:60-64.
581. Kim SY, Byrn R, Groopman J, Baltimore D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: Evidence for differential gene expression. *J Virol*. 1989;63:3708
582. Kinter A, Fauci AS. Interleukin-2 and human immunodeficiency virus infection: Pathogenic mechanisms and potential for immunologic enhancement. *Immunol Res*. 1996;15:1-15.
583. Kinter AL, Ostrowski M, Goletti D, et al. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. *Proc Natl Acad Sci U S A*. 1996;93:14076-14081.
584. Kinter AL, Poli G, Fox L, et al. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. *J Immunol*. 1995;154:2448-2459.
585. Kirchoff F, Greenough TC, Brettler DB, et al. Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. *N Engl J Med*. 1995;332:228-232.
586. Kirk O, Katzenstein TL, Gerstoft J, Mathiesen L, Nielsen H, Pedersen C, Lundgren JD. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. *AIDS* 1999;13:F9-16.

587. Klatzmann D, Barre-Sinoussi F, Nugeyre MT, et al. Selective tropism of lymphadenopathy-associated virus (LAV) for helper-inducer T-lymphocytes. *Science*. 1984;225:59–63
588. Klatzmann D, Champagne E, Chamaret S, et al. T-lymphocyte T4 molecule behaves as receptor for human retrovirus LAV. *Nature*. 1984;312:767–768
589. Klein MR, Keet IPM, D'Amaro J, et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam Cohort of Homosexual Men. *J Infect Dis*. 1994;169:1244–1249.
590. Klein MR, vanBaalen CA, Holwerda AM, et al. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. *J Exp Med*. 1995;181:1365–1372.
591. Klein RS, Harris CA, Small CB, et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. *N Engl J Med*. 1984;311:354–358.
592. Klein SA, Dobmeyer JM, Dobmeyer TS, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. *AIDS*. 1997;11:1111–1118
593. Klotman ME, Kim S, Buchbinder A, et al. Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. *Proc Natl Acad Sci U S A*. 1991;88:5011
594. Knobel H, Miro JM, De-Miguel V, et al. Efficacy of a Short-Term Prednisone Regimen in Nevirapine Associated Rash Prevention: A Double-Blind Placebo-Controlled Clinical Trial. Results of the GESIDA 09/99 Study. Abstract L-15. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2000; Toronto.
595. Koblin BA, McCusker J, Lewis BF, et al. Racial/ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study. *Am J Epidemiol*. 1990;132:837–846
596. Koebner H. Kranken Vorstellung (idiopathisches multiples sarcoma Hemorrhagicum der Extremitaten). *Arch Dermatol Syph (Berl)* 1909;94:121.
597. Koenig S, Earl P, Powell D, et al. Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. *Proc Natl Acad Sci U S A*. 1988;85:8638–8642.
598. Koenig S, Fuerst TR, Wood LV, et al. Mapping the fine specificity of a cytolytic T cell response to HIV-1 *env* protein. *J Immunol*. 1990;145:127–135.
599. Koenig S, Gendelman HE, Orenstein JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. *Science*. 1986;233:1089–1093.
600. Koga Y, Lindstrom E, Fenyo EM, et al. High levels of heterodisperse RNAs accumulate in T cells infected with human immunodeficiency virus and in normal thymocytes. *Proc Natl Acad Sci U S A*. 1988;85:4521–4525.
601. Koga Y, Sasaki M, Yoshida H, et al. Cytopathic effect determined by the amount of CD4 molecules in human cell lines expressing envelope glycoprotein of HIV. *J Immunol*. 1990;144:94–102.
602. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. *Ann Intern Med*. 1997;127:119–125.
603. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. *Science* 2000; 288: 1789-96.
604. Korber B, Theiler J, Wolinsky S. Limitations of a molecular clock applied to considerations of the origin of HIV-1. *Science*. 1998;280:1868.
605. Kotler DP. Wasting syndrome: Nutritional support in HIV infection. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1994;10:931–934.
606. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J Virol*. 1994;68:4650–4655.
607. Koup RA, Sullivan JL, Levine PH, et al. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. *J Virol*. 1989;63:584–590.
608. Koup RA, Sullivan JL, Levine PH, et al. Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. *Blood*. 1989;73:1909–1914.
609. Kovacs J, Lance H, Masur H, et al. A phase III, placebo-controlled trial of recombinant alpha-interferon in asymptomatic individuals seropositive for the acquired immunodeficiency syndrome. *Clin Res*. 1987;35:479A.
610. Kovacs JA, Hiemenz JW, Macher AM, et al. *Pneumocystis carinii* pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. *Ann Intern Med*. 1984;100:663–671.
611. Kovacs JA, Ng VL, Leoung G, et al. Diagnosis of *Pneumocystis* pneumonia: Improved detection in sputum with use of monoclonal antibodies. *N Engl J Med*. 1988;318:589–593.
612. Kovacs JA, O'Neill D, Feuerstein I, et al. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. *Lancet*. 1992;340:637–638.

613. Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *Am J Public Health.* 1998;88:108–113.
614. Kreiss KJ, Coombs R, Plummer F, et al. Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. *J Infect Dis.* 1989;160:380–384.
615. Kristal A, Nasca P, Burnett W, Mikl J. Changes in the epidemiology of non-Hodgkin's lymphoma associated with epidemic human immunodeficiency virus (HIV) infection. *Am J Epidemiol.* 1988;128:711–718.
616. Krivine A, Firtion G, Cao L, et al. HIV replication during the first weeks of life. *Lancet.* 1992;339:1187–1189.
617. Krown S. The role of interferon in the therapy of epidemic Kaposi's sarcoma. *Semin Oncol.* 1987;14(Suppl 3):27–33.
618. Kuhn L, Steketee RW, Weedon J, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. *J Infect Dis.* 1999;179:52–58
619. Kuiken CL, Foley B, Hahn B, Korber B, McCutchan F, Marx PA, et al, eds. *Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.*
620. Kuritzkes DR, Marschner IC, Johnson VA, et al. A randomized, double-blind, placebo-controlled trial of lamivudine (3TC) in combination with zidovudine (ZDV), stavudine (d4T), or didanosine (ddI) in treatment naive patients. Abstract 1. In: *5th Conference on Retroviruses and Opportunistic Infections.* Chicago; 1998:79.
621. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. *N Engl J Med.* 1995;333:1721–1725.
622. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. *N Engl J Med.* 1995;333:1721–1725
623. Ladman R, Peytavin G, Descamps D, Brun Vezinet F, Benech H, Benalisherif A, Trylesinski A, Katlama C, Girard PM, Raffi F, Yeni P, Bentata M, Jarrousee B, Michelet C, Flandre P, and Tonus Study Group. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: The tonus study. *11th Conference on Retroviruses and Opportunistic Infections;* San Francisco; February 8-11, 2004. Abstract 52.
624. Lafrenie RM, Wahl LM, Epstein JS, et al. HIV-1–Tat protein promotes chemotaxis and invasive behavior by monocytes. *J Immunol.* 1996;157:974–977.
625. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factor for HIV-1 transmission in women: Results from a cohort study. *AIDS.* 1993;7:95–102.
626. Laga M, Taelman H, Van der Stuyft P, et al. Advanced immunodeficiency as a risk factor for heterosexual transmission of HIV. *AIDS.* 1989;3:361–366.
627. Lamptey PR, Kamenga MC, Weir SS. Prevention of sexual transmission of HIV in sub-Saharan Africa: Lessons learned. In: Laga M, ed. *AIDS in Africa, 2nd ed.* London: Rapid Science Publishers; 1997:63–77.
628. Landis SE, Schoenbach VJ, Weber DJ, et al. Results of a randomized trial of partner notification in cases of HIV infection in North Carolina. *N Engl J Med.* 1992;326:101–106.
629. Landman, R, Peytavin G, Descamps D, Brun Vezinet F, Benech H, Benalisherif A, Trylesinski A, Katlama C, Girard PM, Raffi F, Yeni P, Bentata M, Jarrousee B, Michelet C, Flandre P, and the Tonus Study Group. *11th Conference on Retroviruses and Opportunistic Infections.* February 8-11, 2004. San Francisco. Abstract 52.
630. Lane H, Feinberg J, Davery V, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. *Lancet.* 1988;2:1218–1222.
631. Lange WR, Synder FR, Lozovsky D, et al. The geographic distribution of human immunodeficiency virus markers in parenteral drug abusers. *Am J Public Health.* 1988;78:443–446
632. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. *Science.* 1995;269:696–699.
633. Lathey JL, Pratt RD, Spector SA. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type I. *J Infect Dis.* 1997;175: 231–232.
634. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. Long-term therapy of chronic hepatitis B with lamivudine. *Hepatology* 2000;32:828-34.
635. Laurence J, Hodsotsev AS, Posnett DN. Superantigen implicated in dependence of HIV-1 replication in T cells on TCR V beta expression. *Nature.* 1992;358:255–259
636. Laurent-Crawford AG, Krust B, Muller S, et al. The cytopathic effect of HIV is associated with apoptosis. *Virology.* 1991;185:829–839
637. Lazzarin A, Saracco A, Musicco M, et al. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. *Arch Intern Med.* 1991;151:2411–2416.
638. Lazzarin A, Saracco A, Musicco M, et al. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. *Arch Intern Med.* 1991;151:2411–2416

639. Learmont J, Tindall B, Evans L, et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. *Lancet*. 1992;340:863–867.
640. Lecuit M, Oksenhendler E, Sarfati C. Use of albendazole for disseminated microsporidian infection in a patient with AIDS. *Clin Infect Dis*. 1994;19:332.
641. Lee BL, Medina I, Benowitz NL, et al. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of *Pneumocystis* pneumonia in patients with the acquired immunodeficiency syndrome (AIDS): Evidence of drug interactions. *Ann Intern Med*. 1989;110:606–611.
642. Lefrere J-J, Roudot-Thoraval F, Mariotti M. The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection. *J Infect Dis*. 1998;177:1541–1548.
643. Lemp GF, Payne SF, Temelso DN, et al. Survival trends for patients with AIDS. *JAMA*. 1990;264:402–405.
644. Leonard R, Zagury D, Desportes I, et al. Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection. *Proc Natl Acad Sci U S A*. 1988;85:33570–3574.
645. Leoung G, Stanford J, Giordano M, et al. A randomized, double-blind trial of TMP/SMX dose escalation vs. direct rechallenge in HIV⁺ persons at risk for PCP and with prior treatment-limiting rash or fever. Abstract No. LB-10. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, September 28–October 1, 1997.
646. Leoung GS, Feigal DW Jr, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against *Pneumocystis carinii* pneumonia—the San Francisco Community Prophylaxis Trial. *N Engl J Med*. 1990;323:769–775.
647. Levine A. Acquired immunodeficiency syndrome-related lymphoma. *Blood*. 1992;80:8.
648. Levine B, Chaisson RE. *Mycobacterium kansasii*: A cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. *Ann Intern Med*. 1991;114:861–868.
649. Levine WC, Revallo R, Kaune V, et al. Decline in sexually transmitted disease prevalence in female Bolivian sex workers: Impact of an HIV prevention project. *AIDS*. 1998;12:1899–1906.
650. Levy J, Hoffman A, Kramer S, et al. Isolation of lymphocytotropic retroviruses from San Francisco patients with AIDS. *Science*. 1984;225:840–842.
651. Levy JA, Greenspan D. HIV in saliva (Letter). *Lancet*. 1988;2:1248.
652. Levy JA, Shimabukuro J, Hollander H, et al. Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. *Lancet*. 1985;2:586–588.
653. Levy JA, Shimabukuro J, Hollander H, et al. Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. *Lancet*. 1985;2:586–588.
654. Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience at UCSF and review of the literature. *J Neurosurg*. 1985;62:475–495.
655. Lewis SH, Reynolds-Kohler C, Fox HE, et al. HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. *Lancet*. 1990;335:565–568.
656. Li CJ, Friedman DJ, Wang C, et al. Induction of apoptosis in uninfected lymphocytes by HIV-1 tat protein. *Science*. 1995;268:429–431.
657. Lieberman J, Fabry JA, Kuo MC, et al. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase. *J Immunol*. 1992;148:2738–2747.
658. Lifson JD, Feinberg MB, Reyes GR, et al. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. *Nature*. 1986;323:725–728.
659. Lifson JD, Reyes GR, McGrath MS, et al. AIDS retrovirus induced cytopathology: Giant cell formation and involvement of CD4 antigen. *Science*. 1986;232:1123–1127.
660. Little SJ. Transmission and prevalence of HIV resistance among treatment-naïve subjects. *Antivir Ther* 2000;5:33-40.
661. Liu Z, Hultin LE, Cumberland WG, et al. Elevated relative fluorescence intensity of CD38 antigen expression on CD8⁺ T cells is a marker of poor prognosis in HIV infection: Results of 6 years of follow-up. *Cytometry*. 1996;26:1–7.
662. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. *Science*. 1994;266:801.
663. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. *Science*. 1994;266:801–805.
664. Louie M, Hurley A, Sun E, Brun S, Ho D, Markowitz M, McGowan I, Ramratnam B, Simon V, Ruiz N. A Regimen containing lopinavir/ritonavir, efavirenz, tenofovir DF, and lamivudine is well-tolerated and more potent than standard HAART. 1st IAS Conference on HIV Pathogenesis and Treatment; July 8-11, 2001; Buenos Aires. Abstract 218.
665. Lucey DR, Pinto LA, Bethke FR, et al. In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1–infected patients. *Clin Diagn Lab Immunol*. 1997;4:43–48.
666. Lucia B, Jennings C, Cauda R, et al. Evidence of a selective depletion of a CD16⁺ CD56⁺ CD8⁺ natural killer cell subset during HIV infection. *Cytometry*. 1995;22:10–15.
667. Luft BJ, Hafner R, Korzun AH. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. *N Engl J Med*. 1993;329:995–1000.

668. Lundgren JD, Barton SE, Lazzarin A, et al. Factors associated with the development of *Pneumocystis carinii* pneumonia in 5,025 European patients with AIDS. *Clin Infect Dis*. 1995;21:106–113.
669. Lundgren JD, Barton SE, Lazzarin A, et al. Factors associated with the development of *Pneumocystis carinii* pneumonia in 5,025 European patients with AIDS. *Clin Infect Dis*. 1995;21:106–113.
670. Lyerly HK, Matthews TJ, Langlois AJ, et al. Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. *Proc Natl Acad Sci U S A*. 1987;84:4601–4605.
671. Lynn WS, Tweedale A, Cloyd MW. Human immunodeficiency virus (HIV-1) cytotoxicity: Perturbation of the cell membrane and depression of phospholipid synthesis. *Virology*. 1988;163:43–51.
672. Lyter DW, Bryant J, Thackeray R, et al. Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men. *J Clin Oncol*. 1995;13:2540–2546.
673. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. *N Engl J Med*. 1995;333:83–88.
674. Macatonia SE, Lau R, Patterson S, et al. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. *Immunology*. 1990;71:38–45.
675. Maciaszek J, Parada N, Cruikshank W, et al. IL-16 represses HIV-1 promoter activity. *J Immunol*. 1997;158:5–8.
676. Mackewicz C, Balckbourn DJ, Levy JA. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. *Proc Natl Acad Sci U S A*. 1995;92:2308–2312.
677. MacMahon E, Glass J, Hayward S, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. *Lancet*. 1991;338:969.
678. Maddon PJ, Dalgleish AG, McDougal JS, et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. *Cell*. 1986;47:333–348.
679. Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. *Clin Infect Dis*. 1996;173:219
680. Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. *Science*. 1994;265: 244–248.
681. Magura S, Grossman JI, Lipton DS, et al. Determinants of needle sharing among intravenous drug users. *Am J Public Health*. 1989;79:459–462.
682. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *Lancet*. 2002 Mar 2;359(9308):727-32.
683. Mallory DL, Parrillo JE, Bailey KR, et al. Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate. *Crit Care Med*. 1987;15:503–505.
684. Manca F, Habeshaw JA, Dalgleish AG. HIV envelope glycoprotein, antigen specific T-cell responses, and soluble CD4. *Lancet*. 1990;335:811–815.
685. Mandelbrot L, Landreau-Mascaro A, Rekecewicz C, et al. for the Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine-Zidovudine Combination for Prevention of Maternal-Infant Transmission of HIV-1. *JAMA*. 2001;285(16):2083-2093.
686. Marcus R, Culver DH, Bell DM, et al. Risk of human immunodeficiency virus infection among emergency department workers. *Am J Med*. 1993;94:363–370.
687. Marder K, Liu X, Stern Y, et al. Neurologic signs and symptoms in a cohort of homosexual men followed for 4.5 years. *Neurology*. 1995;45:261–267.
688. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of zidovudine, an inhibitor of HIV-1 protease, to treat HIV-1 infection. *N Engl J Med*. 1995;333:1534–1539.
689. Marks G, Richardson JL, Maldonado N. Self-disclosure of HIV infection to sexual partners. *Am J Public Health*. 1991;81:1321–1323.
690. Marshall DW, Brey RL, Cahill WT, et al. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. *Arch Neurol*. 1988;45:954–958.
691. Marshall DW, Brey RL, Cahill WT, et al. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. *Arch Neurol*. 1988;45:954–958.
692. Martinez E, Miro JM, Gonzalez J, et al. Withdrawal of *Mycobacterium avium* complex suppressive therapy in HIV-1 infected patients on highly active antiretroviral therapy. *AIDS*. 1999;13:147–148.
693. Masur H, et al. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. *N Engl J Med*. 1990;323:1500–1504.
694. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired *Pneumocystis carinii* pneumonia: Initial manifestations of cellular immune dysfunction. *N Engl J Med*. 1981;305:1431.
695. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. *Ann Intern Med*. 1992;111:223–231.
696. Masur H, Polis MA, Tuazon CU, et al. Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS. *J Infect Dis*. 1993;167:1422–1426.
697. Masur H. Prevention and treatment of *Pneumocystis* pneumonia. *N Engl J Med*. 1992;327:1853–1860.

698. Mathews C, Barba D, Fullerton SC. Early biopsy versus empiric treatment with delayed biopsy of non-responders in suspected HIV associated cerebral toxoplasmosis: A decision analysis. *AIDS*. 1995;9:1243.
699. Matthews TJ, Langlois AJ, Robey WG, et al. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. *Proc Natl Acad Sci U S A*. 1986;83:9709–9713.
700. Mayeux R, Tang M, Tocad G, et al. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. *Neurology*. 1993;43:176–182.
701. Mazza DS, Grieco MH, Reddy MM, et al. Serum IgE in patients with human immunodeficiency virus infection. *Ann Allergy Asthma Immunol*. 1995;74: 411–414.
702. McArthur JC, Cohen BA, Farzadegan H. Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings. *Ann Neurol*. 1988;23:S34–S37.
703. McArthur JC, Cohen BA, Farzadegan H. Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings. *Ann Neurol*. 1988;23:S34–S37.
704. McCusker J, Koblin B, Lewis BF, et al. Demographic characteristics, risk behaviors, and HIV seroprevalence among intravenous drug users by site of contact: Results from a communitywide HIV surveillance project. *Am J Public Health*. 1990;80:1062–1067
705. McDonald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. *Arch Intern Med*. 1997;157:951–959.
706. McNeil C. HIV infection with Hodgkin's disease: The virus makes a difference (News). *J Natl Cancer Inst*. 1997;89:754–755.
707. Medina I, Mills J, Leoung G, et al. Oral therapy for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome—a controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. *N Engl J Med*. 1990;323:776–782.
708. Melbye M, Grossman RJ, Goedert JJ, et al. Risk of AIDS after herpes zoster. *Lancet*. 1987;728–731.
709. Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal cancer incidence in the United States, 1940–1989. *Am J Epidemiol*. 1994;139:772–780.
710. Mellors J, Lederman M, Haas D, et al. Antiretroviral effects of therapy combining abacavir (1592) with HIV protease inhibitors (PIs). Abstract 4. In: 5th Conference on Retroviruses and Opportunistic Infections. Chicago; 1998:79.
711. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. *Ann Intern Med*. 1995;122:573–579.
712. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4⁺ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med*. 1997;126:946–954.
713. Mellors JW, Rinaldo CR, Phalguni G, et al. Prognosis in HIV-1 infection predicted by quantity of virus in plasma. *Science*. 1996;272:1167–1170.
714. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. *Ann Intern Med*. 1992;116:13–20
715. Merck Research Laboratories. Letter to investigators. April 8, 1998.
716. Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. *J Infect Dis*. 1996;173:355–364.
717. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with zidovudine in HIV-infected patients. *AIDS*. 1997;11:F29–F33.
718. Meyaard L, Otto S, Keet I, vanLier R, et al. Changes in cytokine secretion patterns of CD4⁺ T-cell clones in human immunodeficiency virus infection. *Blood*. 1994;84:4262–4268
719. Meyaard L, Otto SA, Jonker RR, et al. Programmed death of T cells in HIV-1 infection. *Science*. 1992;257:217–219
720. Meyaard L, Otto SA, Keet IP, et al. Programmed death of T cells in human immunodeficiency virus infection. No correlation with progression to disease. *J Clin Invest*. 1994;93:982–988.
721. Meyaard L, Schuitemaker H, Miedema F. T-cell dysfunction in HIV infection: Anergy due to defective antigen-presenting cell function? *Immunol Today*. 1993;14:161–164
722. Meyers G, Berzofsky JA, Korber B, et al. *Human Retroviruses and AIDS*. Los Alamos National Laboratory, New Mexico, 1992.
723. Michael N, Chang G, Louie L, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. *Nat Med*. 1997;3:338–340.
724. Michael NL, Chang G, D'arcy LA, et al. Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. *J Virol*. 1995;69:4228–4236.
725. Michael NL, Chang G, D'arcy LA, et al. Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression. *J Virol*. 1995;69:6758–6769.
726. Michael NL, Nelson JA, KewalRamani VN, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. *J Virol*. 1998;72:6040–6047

727. Michael NL, Vahey M, Burke RS, et al. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: Evidence for viral replication in all stages of HIV disease. *J Virol.* 1992;66:310–316.
728. Miedema F. Immunological abnormalities in the natural history of HIV infection: Mechanisms and clinical relevance. *Immunodeficiency Rev.* 1992;3:173–193.
729. Miles SA. Pathogenesis of AIDS-related Kaposi's sarcoma. Evidence of a viral etiology. *Hematol Oncol Clin North Am.* 1996;10:1011–1021.
730. Miller MD, Margot N, Coakley D, Cheng A. Anti-HIV responses and development of RT mutations in antiretroviral-experienced patients adding tenofovir DF (TDF) therapy: Baseline and Week 24 genotypic analyses of Study 907. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago. Abstract 1928.
731. Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. *Nucleosides Nucleotides Nucleic Acids* 2001;20:1025-8.
732. Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, Cherrington JM. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. *J Acquir Immune Defic Syndr* 2001;27:450-8.
733. Miller MD, Margot NA, Lu B. Effect of baseline nucleoside-associated resistance on response to tenofovir DF (TDF) therapy: Integrated analyses of studies 902 and 907. 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002; Seattle. Abstract 43.
734. Mills J, Leoung G, Medina J, et al. Dapsone treatment of *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome. *Antimicrob Agents Chemother.* 1988;32:1057–1060.
735. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-2'-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy associated virus in vitro. *Proc Natl Acad Sci U S A.* 1985;82:7096.
736. Mitsuyasu R, Groopman J. Biology and therapy of Kaposi's sarcoma. *Semin Oncol.* 1984;11:53–59.
737. Mitsuyasu RT, Skolnik PR, Cohen SR, et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naïve patients. NV15355 Study Team. *AIDS.* 1998;12:F103–F109.
738. Mizusawa H, Hirano A, Llena JF, Shintaku M. Cerebrovascular lesions in acquired immune deficiency syndrome (AIDS). *Acta Neuropathol.* 1988;76:451–457.
739. MMWR (a) Morb Mortal Wkly Rep. 1992;41(RR-17):1–19.
740. MMWR (b) Morb Mortal Wkly Rep. 1992;42(RR-17)
741. Mocroft A, Bofill M, Lipman M, et al. CD8+, CD38+ lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1997;14:158–162.
742. Molina JM, Ferchal F, Rancinan C, Yeni P, Rozenbaum W, Journot V, Morand-Joubert L, Fournier S, Morlat P, Dupont B, Delfraissy JF, Dellamonica P, Poizot-Martin I, Rosenthal E, Chene G. Once-daily Combination of Emtricitabine, Didanosine, and Efavirenz vs Continued PI-based HAART in HIV-infected Adults with Undetectable Plasma HIV-RNA: 48-week Results of a Prospective Randomized Multicenter Trial (ALIZE-ANRS 99). 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003. Abstract 551.
743. Molina JM, Goguel J, Sarfati C, et al. Drug screening for treatment of *Enterocytozoon bienersi* infections in patients with HIV infection (ANRS 034). Abstract No. 687. In: Abstracts of the Fourth International Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22–26, 1996.
744. Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to *Septata intestinalis* in patients with AIDS: Clinical features and response to albendazole therapy. *J Infect Dis.* 1995;171:245.
745. Monini P, de Lellis L, Fabris M, et al. Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. *N Engl J Med.* 1996;334:1168–1172.
746. Montagnier L. *Virus.* New York: Norton, 2000.
747. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. *JAMA.* 1998;279:930–937.
748. Montaner JS, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. *J Infect Dis.* 1997;175:801–806.
749. Montaner JSG, Lawson LM, Gervais A, et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related *Pneumocystis carinii* pneumonia: A randomized, placebo-controlled study. *Ann Intern Med.* 1991;114:948–953.
750. Montefiori DC, Pantaleo G, Fink LM, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. *J Infect Dis.* 1996;173:60–67.
751. Moore RD, Hidalgo J, Sugland B, et al. Zidovudine and the natural history of the acquired immunodeficiency syndrome. *N Engl J Med.* 1991;324:1412–1416.
752. Moorman A, Von Bargen J, Palella F, et al. Determinants of “breakthrough” *Pneumocystis carinii* pneumonia (PCP) in the HIV outpatient study (HOPS). Abstract No. 294. In: Abstracts of the Fourth Conference on

- Retroviruses and Opportunistic Infections, American Society of Microbiology, Washington, DC; January 22–26, 1997.
753. Morgello S, Block GA, Price RW, Petito CK. Varicella-zoster virus leukoencephalitis and cerebral vasculopathy. *Arch Pathol Lab Med.* 1988;112:173–177.
 754. Morris JT, Kelly JW. Effective treatment of cerebral toxoplasmosis with doxycycline. *Am J Med.* 1992;93:107.
 755. Moses S, Plummer FA, Ngugi E, et al. Controlling HIV in Africa: Effectiveness and cost of an intervention in a high-frequency STD transmitter core group. *AIDS.* 1991;5:407–411. 73. Laga M, Alary M, Nzila N, et al. Condom promotion and STD treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. *Lancet.* 1994;344:2446–2448.
 756. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS-related condition: Three year follow up of the San Francisco General Hospital Cohort. *BMJ.* 1988;296:745–750.
 757. Moss AR, Osmond D, Bacchetti P, et al. Risk factors for AIDS and HIV seropositivity in homosexual men. *Am J Epidemiol.* 1987;125:1035–1047.
 758. Moss GB, Overbaugh J, Welch M, et al. Human immunodeficiency virus DNA in urethral secretions in men: Association with gonococcal urethritis and CD4 depletion. *J Infect Dis.* 1995;172:1469–1474
 759. Moss PA, Rowland-Jones SL, Frodsham PM, et al. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. *Proc Natl Acad Sci U S A.* 1995;92:5773–5777.
 760. Moyle G, Maitland D, Hand J, Mandalia S, Nelson M, Gazzard B. Early virological failure in persons with viral loads >100,000 cps/ml and CD4 counts <200 cells/mm³ receiving ddI/tenofovir/efavirenz as initial therapy: results from a randomized comparative trial. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30 - November 2, 2004; Washington, DC. Abstract H-566.
 761. Moyle G, Maitland D, Hand J, Mandalia S, Nelson M, Gazzard B. Early virological failure in persons with viral loads >100,000 cps/ml and CD4 counts <200 cells/mm³ receiving ddI/tenofovir/efavirenz as initial therapy: results from a randomized comparative trial. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract H-566.
 762. Moyle G, Pozniak A, Opravil M, Clumeck N, DelFraissy JF, Johnson M, Pelgrom J, Reynes J, Vittecoq D, DeLora P, Salgo M, Duff F. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. *Study of Protease Inhibitor Combinations in Europe. J Acquir Immune Defic Syndr* 2000;23:128-37.
 763. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. *Clin Ther* 2000;22:911-36; discussion 898.
 764. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. *Clin Ther* 2000;22:911-36; discussion 898
 765. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. *Clin Ther* 2000;22:911-36; discussion 898.
 766. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. *Clin Ther.* 2000 Aug;22(8):911-36; discussion 898.
 767. Muller F, Rollag H, Froland SS. Reduced oxidative burst responses in monocytes and monocyte-derived macrophages from HIV-infected individuals. *Clin Immunol Immunopathol.* 1990;82:10–15.
 768. Muller H, Weier S, Kojouharoff G, et al. Distribution and infection of Langerhans cells in the skin of HIV-infected healthy subjects and AIDS patients. *Res Virol.* 1993;144:59–67
 769. Mummaneni V, Randall D, Chabuel D, Geraldles M, O'Mara E. Steady-State Pharmacokinetic (PK) Interaction Study of Atazanavir (ATV) with Clarithromycin (CLR) in Healthy Subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002, Abstract H1717.
 770. Muñoz A, Schragger L, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985–1991. *Am J Epidemiol.* 1993;137:423–438.
 771. Murayama T, Cai Q, Rinaldo CR. Antibody-dependent cellular cytotoxicity mediated by CD16+ lymphocytes from HIV-seropositive homosexual men. *Clin Immunol Immunopathol.* 1990;55:297–304.
 772. Muro-Cacho CA, Pantaleo G, Fauci AS. Analysis of apoptosis in lymph nodes of HIV-infected persons. *J Immunol.* 1995;154:5555–5566
 773. Murphy RL, Gulick RM, DeGruttola V, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. *J Infect Dis.* 1999;179:808–816.
 774. Murphy RL, Lavelle JP, Allan JD, et al. Aerosol pentamidine prophylaxis following *Pneumocystis carinii* pneumonia in AIDS patients: Results of a blinded dose-comparison study using an ultrasonic nebulizer. *Am J Med.* 1991;90:418–426.
 775. Murray HW, Godbold JH, Jurica KB, Roberts RB. Progression to AIDS in patients with lymphadenopathy or AIDS-related complex: Reappraisal of risk and predictive factors. *Am J Med.* 1989;86:533–538.

776. Murray HW, Godbold JH, Jurica KB, Roberts RB. Progression to AIDS in patients with lymphadenopathy or AIDS-related complex: Reappraisal of risk and predictive factors. *Am J Med.* 1989;86:533–538.
777. Musey L, Hughes J, Schacker T, et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. *N Engl J Med.* 1997;337:1267–1274.
778. Musicco M, Lazzarin A, Nicolasi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission: Italian Study Group on HIV Heterosexual Transmission. *Arch Intern Med.* 1994;154:1971–1976.
779. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. *J Virol.* 1993;67:6642–6647.
780. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. *Nature.* 1987;326:711.
781. Naif HM, Li S, Ho-Shon M, et al. The state of maturation of monocytes into macrophages determines the effects of IL-4 and IL-13 on HIV replication. *J Immunol.* 1997;158:501–511.
782. Naimi N, Plancherel C, Bosser C, et al. Anticardiolipin antibodies in HIV-negative and HIV-positive hemophiliacs. *Blood Coagul Fibrinolysis.* 1990;1:5–8.
783. Nakagawa M, Maruyama Y, Sugita H, Osame M. Nationwide survey of neurologic manifestations of acquired immunodeficiency syndrome in Japan. *Intern Med.* 1997;36:175–178.
784. Nasr S, Brynes R, Garrison C, Chan W. Peripheral T-cell lymphoma in a patient with acquired immunodeficiency syndrome. *Cancer.* 1988;61:947–951.
785. National Commission on AIDS. Behavioral and social sciences and the HIV/AIDS epidemic. National Commission on AIDS, Washington, DC, 1993
786. Navia BA, Cho E-S, Petitto CK, Price RW. The AIDS dementia complex: II. Neuropathology. *Ann Neurol.* 1986;19:525–535.
787. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. *Ann Neurol.* 1986;19:517–524.
788. Navin TR, Fontaine RE. Intravenous versus intramuscular administration of pentamidine. *N Engl J Med.* 1984;311:1701–1702.
789. Neaigus A, Sufian M, Friedman SR, et al. Effects of outreach intervention on risk reduction among intravenous drug users. *AIDS Educ Prev.* 1990;2:253–271
790. Nelson KE, Celentano DD, Eiumtrakol S, et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. *N Engl J Med.* 1996;335:297–303.
791. Nelson KE, Vlahov D, Cohn S, et al. Sexually transmitted diseases in a population of intravenous drug users: Association with seropositivity to the human immunodeficiency virus (HIV). *J Infect Dis.* 1991;164:457–463
792. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, Pillay D, Fisher M, Bower M, Gazzard B. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. *AIDS.* 2003 Jan 3;17(1):F7-F10.
793. Newcomer VD. Human immunodeficiency virus infection and acquired immunodeficiency syndrome in the elderly (Letter). *Arch Dermatol.* 1997;133:1311–1312.
794. Nickoloff B, Foreman K. Charting a new course through the chaos of KS (Kaposi's sarcoma). *Am J Pathol.* 1996;148:1323–1329.
795. Nielsen TL, Eeftinck Schattenkerk JK, Jensen BN, et al. Adjunctive corticosteroid therapy for *Pneumocystis carinii* pneumonia in AIDS: A randomized European multicenter open label study. *J Acquir Immune Defic Syndr.* 1992;5:726–731.
796. Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Cohen C, McGovern R, Adler E, McLaren C. Antiviral Efficacy, Metabolic Changes and Safety of Atazanavir (ATV) Versus Lopinavir/Ritonavir (LPV/RTV) in Combination with 2 NRTIs in Patients Who Have Experienced Virologic Failure with Prior Pi-Containing Regimen(s): 24-Week Results from BM. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, July 13-16, 2003. Abstract 117.
797. Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type I infection: Review of pathogenesis and early treatment intervention in human and animal retrovirus infections. *J Infect Dis.* 1993;168:1490–1501.
798. Niwa Y, Yano M, Futaki S, et al. T-cell membrane-associated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120. *Eur J Biochem.* 1996;237:64–70.
799. Nixon DF, Townsend AR, Elvin JG, et al. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. *Nature.* 1988;336:484–487.
800. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. *J Clin Oncol.* 1997;15:653–659.
801. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. *J Clin Oncol.* 1998;16:2445–2451.

802. Noskin GA, Murphy RL, Black JR, Phair JP. Salvage therapy with clindamycin/primaquine for *Pneumocystis carinii* pneumonia. Clin Infect Dis. 1992;14:183–188.
803. Notermans DW, Jurriaans S, de Wolf F, Foudraine NA, de Jong JJ, Cavert W, Schuwirth CM, Kauffmann RH, Meenhorst PL, McDade H, Goodwin C, Leonard JM, Goudsmit J, Danner SA. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with zidovudine, zalcitabine and zalcitabine. Ritonavir/3TC/ZDV Study Group. AIDS 1998;12:167-73.
804. Nunez M, Soriano V, Martin-Carbonero L, Rodriguez-Rosado R, Diaz B, Gonzalez-Lahoz J. The SENC trial: a randomized, open-label study comparing efavirenz versus nevirapine. Results at 48 weeks. The XIV International AIDS Conference, Barcelona, July, 2002. Abstract TuPeB4441.
805. Oberlin E, Amara A, Bachelier F, et al. The CXCR4 chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996;382:833–835
806. O'Brien JG, Dong BJ, Coleman RL, et al. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for *Pneumocystis carinii* pneumonia. Clin Infect Dis. 1997;24:854–859.
807. O'Brien S. AIDS: A role for host genes. Hosp Pract. 1998;33:53.
808. O'Brien T, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5Δ32. Lancet. 1997;349:1219
809. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA. 1996;276:105–110.
810. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood. 1995;86:1082–1089.
811. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4⁺ lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996;334:426–431.
812. O'Doherty MJ, Thomas S, Page C, et al. Differences in relative efficacy of nebulizers for pentamidine administration. Lancet. 1988;2:1283–1286.
813. Ogg G, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103–2106.
814. Ognibene FP, Shelhamer J, Gill V, et al. The diagnosis of *Pneumocystis carinii* pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage. Am Rev Respir Dis. 1984;129:933–937.
815. Ojo-Amaize EA, Nishanian P, Keith DE, et al. Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells. J Immunol. 1987;139:2458–2463.
816. Oliva A, Kinter AL, Vaccarezza M, et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest. 1998;102:223–231.
817. O'Mara E, Mummaneni V, Bifano M, Randall D, Uderman H, Knox L, Gerald M. Steady-State Pharmacokinetic Interaction Study Between BMS-232632 and Ritonavir in Healthy Subjects. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Sept. 4-8, 2001, Abstract 740.
818. Opravil M, Marincek B, Fuchs WA, et al. Shortcomings of chest radiography in detecting *Pneumocystis carinii* pneumonia. J Acquir Immun Defic Syndr. 1993;7:39–45.
819. O'Riordan TG, Smaldone GC. Exposure of health care workers to aerosolized pentamidine. Chest. 1992;101:1494–1499.
820. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A. 1989;86:2336–2340
821. Osmond D, Chaisson RE, Moss A, et al. Lymphadenopathy in asymptomatic patients seropositive for HIV. N Engl J Med. 1987;317:246.
822. Oyaizu N, McCloskey TW, Coronese M, et al. Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood. 1993;82:3392–3400
823. Packer SJ, Cesario T, Williams JH Jr. *Mycobacterium avium* complex infection presenting as endobronchial lesions in immunosuppressed patients. Ann Intern Med. 1988;109:389–393.
824. Padian NS, Shiboski SC, Jewell NP. Female-to-male transmission of human immunodeficiency virus. JAMA. 1991;266:1664–1667
825. Padian NS, Shiboski SC, Jewell NP. The effect of number of exposures on the risk of heterosexual HIV transmission. J Infect Dis. 1990;161:883–887
826. Pakker NG, Kroon ED, Roos MTL, et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS. 1999;13:203–212.
827. Palasithran P, Ziegler JB, Stewart GJ, et al. Breastfeeding during primary human immunodeficiency virus infection and risk of transmission from mother to infant. J Infect Dis. 1993;167:441
828. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.

829. Palker TJ, Clark ME, Langlois AJ, et al. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. *Proc Natl Acad Sci U S A.* 1988;85:1932–1936.
830. Pallesen G, Gerstoft J, Mathiesen L. Stages in LAV/HTLV-III lymphadenitis: I. Histological and immunohistological classification. *Scand J Immunol.* 1987;25: 83–91.
831. Pantaleo G, Butini L, Graziosi C, et al. Human immunodeficiency virus (HIV) infection in CD4+ T lymphocytes genetically deficient in LFA-1: LFA-1 is required for HIV-mediated cell fusion but not for viral transmission. *J Exp Med.* 1991;173:511–514.
832. Pantaleo G, Demarest JF, Schacker T, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. *Proc Natl Acad Sci U S A.* 1997;94:254–258.
833. Pantaleo G, Demarest JF, Soudeyns H, et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. *Nature.* 1994;370:463–467.
834. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. *Annu Rev Microbiol.* 1996;50:825–854.
835. Pantaleo G, Graziosi C, Butini L, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. *Proc Natl Acad Sci U S A.* 1991;88:9838–9842.
836. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. *Nature.* 1993;362:355–358
837. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. *Nature.* 1993;362:355–358.
838. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subject with long-term nonprogressive human immunodeficiency virus infection. *N Engl J Med.* 1995;332:209–216.
839. Pape JW, Verdier RI, Boney M, et al. Cyclospora infection in adults infected with HIV: Clinical manifestations, treatment, and prophylaxis. *Ann Intern Med.* 1994;121:654.
840. Pape JW, Verdier RI, Johnson WD Jr. Treatment and prophylaxis of *Isospora belli* infection in patients with the acquired immunodeficiency syndrome. *N Engl J Med.* 1989;320:1044.
841. Para MF, Dohn M, Fram P, et al. ACTG 268 Trial—gradual initiation of trimethoprim/sulfamethoxazole (T/S) as primary prophylaxis for *Pneumocystis carinii* pneumonia (PCP). Abstract No. 2. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, American Society of Microbiology, Washington, DC; January 22–26, 1997.
842. Park YD, Belman AL, Kim TS. Stroke in pediatric acquired immunodeficiency syndrome. *Adv Neurol.* 1990;28:303–311.
843. Pasquier, C., P.Y. Bello, P. Gourney, J. Puel, and J. Izopet. A new generation of serum anti-HIV antibody immunocapture assay for saliva testing. *Clin Diag Virol* 1997; 8: 195–197.
844. Paterson DL, Georghiou PR, Allworth AM, et al. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. *Clin Infect Dis.* 1995;20;250–254.
845. Paton P, Poly H, Gonnaud P. Acute meningoradiculitis concomitant with seroconversion to human immunodeficiency virus type 1. *Res Virol.* 1990;141:427–433.
846. Paul DA, Falk LA, Kessler HA, et al. Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. *J Med Virol.* 1987;22: 357–363.
847. Pavia AT, Benyo M, Niler L, et al. Partner notification for control of HIV: Results after 2 years of a statewide program in Utah. *Am J Public Health.* 1993;83:1418–1424.
848. Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. *Nat Med.* 1996;2:412–417
849. Pedersen C, Katzenstein T, Nielsen C, et al. Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: Relation to CD4 cell count and clinical course of primary infection. *J Acquir Immun Defic Syndr Hum Retrovirol.* 1997;16:93–99.
850. Peeters M. Recombinant HIV sequences: their role in the global epidemic. In: Human retroviruses and AIDS 2000: a compilation and analysis of nucleic acid and amino acid Sequences. Kuiken CL, Foley B, Hahn B, et al, eds. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM
851. Penn I. Cancers of the anogenital region in renal transplant recipients: Analysis of 65 cases. *Cancer.* 1986;58:611–616.
852. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. *Nature.* 1997;387:188–191.
853. Perlman DC, El-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. *Clin Infect Dis.* 1997;25:242–246
854. Peterman TA, Lui KJ, Lawrence DN, et al. Estimating the risks of transfusion-associated acquired immune deficiency syndrome and human immunodeficiency virus infection. *Transfusion.* 1987;27:371–374.
855. Peterman TA, Stoneburner RL, Allen JR, et al. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. *JAMA.* 1988;59:55–58.
856. Peters M, Anderson J, Lynch P, Jacobson J, Sherman K, Alston Smith B, Swindells S, Liu T, Johnson V, Pollard R, Rooney J, Polsky B, and AACTG 5127 team. Tenofovir Disoproxil Fumarate Is Not Inferior to Adefovir Dipivoxil for the Treatment of Hepatitis B Virus in Subjects Who Are Co-infected with HIV:

- Results of ACTG A5127. 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston. Abstract 124.
857. Petrukevitch A, Del Amo J, Phillips AN, et al. Disease progression and survival following specific AIDS-defining conditions: A retrospective cohort study of 2048 HIV-infected persons in London. *AIDS*. 1998;12:107-113.
 858. Phuapradit W. Timing and mechanism of perinatal human immunodeficiency virus-1 infection. *Aust N Z J Obstet Gynaecol*. 1998;38:293-297.
 859. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated *Mycobacterium avium* complex infection in patients with advanced acquired immunodeficiency syndrome. *N Engl J Med*. 1996;335:384-391.
 860. Pinto AN. AIDS and cerebrovascular disease. *Stroke*. 1996;27:538-543.
 861. Piot P, Laga M. Genital ulcers, other sexually transmitted diseases, and the sexual transmission of HIV. The first two may be important risk factors for the third. *BMJ*. 1989;298:623-624.
 862. Piscitelli S, Bechtel C, Sadler B, Falloon J. The Addition of a Second Protease Inhibitor Eliminates Amprenavir-Efavirenz Drug Interactions and Increases Plasma Amprenavir Concentrations. Abstract 78. 7th Conference on Retroviruses and Opportunistic Infections. January 30 - February 2, 2000; San Francisco.
 863. Plata F, Autran B, Martins LP, et al. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. *Nature*. 1987;328:348-351.
 864. Plummer FA, Simonsen JN, Cameron DW, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. *J Infect Dis*. 1991;163:233-239.
 865. Podzamczak D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, Gonzalez A, Pedrol E, Lozano L, Ocana I, Llibre JM, Casiro A, Aranda M, Barrufet P, Martinez-Lacasa J, Miro JM, Badia X, Casado A, Lupo S, Cahn P, Manos M, Estela J. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). *Antivir Ther*. 2002 Jun;7(2):81-90.
 866. Podzamczak D, Ferrer E, Gatell JM, et al. Early virological failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. *Antivir Ther*. 2004;9:S172.
 867. Podzamczak D, Ferrer E, Gatell JM, et al. Early virological failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. *Antivir Ther*. 2004;9:S172.
 868. Poiesz BJ, Ruscetti FW, Reitz MS, et al. Isolation of a new type-C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. *Nature*. 1981;294:2686.
 869. Pokrovsky VV, Eramova EU. Nosocomial outbreak of HIV infection in Elista, USSR. Abstract W.A.O.5. Presented at the Fifth International Conference on AIDS. Montreal, June 4-9, 1989.
 870. Poli G, Botazzi B, Acero R, et al. Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: Selective impairment of chemotaxis. *Clin Exp Immunol*. 1985;62: 136-142.
 871. Poli G, Fauci A. Role of cytokines in the pathogenesis of human immunodeficiency virus infection. In: Aggarwal B, Puri R, eds. *Human Cytokines: Their Role in Disease and Therapy*. Cambridge, Mass: Blackwell Science; 1995:421-449.
 872. Polk BF, Fox R, Brookmeyer R, et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. *N Engl J Med*. 1987;316:61-66.
 873. Polk BF, Fox R, Brookmeyer R, et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. *N Engl J Med*. 1987;316:61-66.
 874. Polyak S, Chen H, Hirsch D, et al. Impaired class II expression and antigen uptake in monocytic cells after HIV-1 infection. *J Immunol*. 1997;159:2177-2188.
 875. Pope M, Frankel SS, Mascola JR, et al. Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. *J Virol*. 1997;71:8001-8007
 876. Popovic M, Sarngadharan M, Read E, et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. *Science*. 1984;224:497-500.
 877. Popovic M, Sarngadharan MG, Read E, et al. A method for the detection, isolation, and continuous production of cytopathic human T-lymphotropic retroviruses of the HTLV family (HTLV-III) from patients with AIDS and pre-AIDS. *Science*. 1984;224:497
 878. Porter S, Sande M. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. *N Engl J Med*. 1992;327:1643-1648.
 879. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. *N Engl J Med*. 1992;327:1643-1648.
 880. Posnett DN, Kabak S, Dobrescu D, et al. The HIV-1 reservoir in distinct V beta subsets of CD4 T cells: Evidence for a putative superantigen. *J Clin Immunol*. 1995;15(Suppl):18S-21S.
 881. Posnett DN, Kabak S, Hochtsev A, et al. T-cell antigen receptor V beta subsets are not preferentially deleted in AIDS. *AIDS*. 1993;7:625-631
 882. Powderly W, Sension M, Conant M, et al. The efficacy of Viracept (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or

- AZT/3TC. Abstract 370. In: 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997:132.
883. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: The end of opportunism? *JAMA*. 1998;280:72–77.
884. Poznansky MC, Walker B, Haseltine WA, et al. A rapid method for quantitating the frequency of peripheral blood cells containing HIV-1 DNA. *J Acquir Immune Defic Syndr*. 1991;4:368–373.
885. Presant C, Gala K, Wiseman C, et al. Human immunodeficiency virus-associated T-cell lymphoblastic lymphoma in AIDS. *Cancer*. 1987;60:1459–1461.
886. Preston S, Piliero P, O'Mara E, Mummaneni V, Randall D, Morvillo C, Geraldine M, Agarwala S, Drusano G. Evaluation of Steady-State Interaction between Atazanavir (ATV) and Efavirenz (EFV). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 24–28, 2002, Abstract 443-W.
887. Prochaska, J.O., DiClemente, C.C., and Norcross, J.C. In search of how people change: application to addictive behaviors. *Am Psychol*, 1992; 47: 1102–1114.
888. Pu R, Coleman J, Omori M, et al. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. *AIDS* 2001; 15: 1225–37
889. Putney SD, Matthews TJ, Robey WG, et al. HTLV-III/LAV-neutralizing antibodies to an *E. coli*-produced fragment of the virus envelope. *Science*. 1986;234:1392–1395.
890. Quinn TC. Acute primary HIV infection. *JAMA*. 1997;278:58–62.
891. Quinn TC. Association of sexually transmitted diseases and infection with the human immunodeficiency virus: Biological cofactors and markers of behavioral interventions. *Int J STD AIDS*. 1996;7(Suppl 2):S17–S24.
892. Quinn TC. Global burden of the HIV pandemic. The epidemiology of the acquired immunodeficiency syndrome in the 1990s. *Lancet*. 1996;348:99–106.
893. Quinnan GV, Masur H, Rook AH, et al. Herpesvirus infections in the acquired immunodeficiency syndrome. *JAMA*. 1984;252:72–77.
894. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. *Lancet*. 1998;351:252–255.
895. Racz P, Tenner-Racz K, Kahl C, et al. Spectrum of morphologic changes of lymph nodes from patients with AIDS or AIDS-related complexes. *Prog Allergy*. 1986;37:81–181.
896. Rana S, Besson G, Cook DG, et al. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: Resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation. *J Virol*. 1997;71:3219–3227
897. Randomised trial of addition of lamivudine or lamivudine plus zidovudine to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial. *Lancet*. 1997;349:1413–1421.
898. Raport C, Gosling J, Schweickart V, et al. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. *J Biol Chem*. 1996;271:17161–17166
899. Rasheed S, Li Z, Xu D, Kovacs A. Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood in human immunodeficiency virus-infected women. *Am J Obstet Gynecol*. 1996;175:122–129
900. Ravalli S, Chabon A, Khan A. Gastrointestinal neoplasia in young HIV-positive patients. *Am J Clin Pathol*. 1989;91:458–461.
901. Real F, Oettgen H, Krown S. Kaposi's sarcoma and the acquired immunodeficiency syndrome: Treatment with high and low doses of leukocyte A interferon. *J Clin Oncol*. 1986;4:544–551.
902. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. *Nat Med*. 1998;4:679
903. Reitz MS, Wilson C, Naugle C, et al. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. *Cell*. 1988;54:57–63.
904. Remick S. Non-AIDS-defining cancers. *Hematol Oncol Clin North Am*. 1996;10:1203–1213.
905. Report of a Consensus Workshop, Siena, Italy, January 17–18, 1992. Early diagnosis of HIV infection in infants. *J Acquir Immune Defic Syndr*. 1992;5:1169–1178
906. Resnick L, Berger JR, Shapshak P, Tourtellotte WW. Early penetration of the blood-brain barrier by HIV. *Neurology*. 1988;38:9–14.
907. Resnick L, Berger JR, Shapshak P, Tourtellotte WW. Early penetration of the blood-brain barrier by HIV. *Neurology*. 1988;38:9–14.
908. Resnick L, Dimarzo-Veronese F, Schupbach J. Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex. *N Engl J Med*. 1985;313:1498–1504.
909. Resnick L, Dimarzo-Veronese F, Schupbach J. Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex. *N Engl J Med*. 1985;313:1498–1504.

910. Reynes J, Peyriere H, Merle de Boever C, Le Moing V. Renal tubular injury and severe hypophosphoremia (Fanconi syndrome) associated with tenofovir therapy. 10th Conference on Retroviruses and Opportunistic Infections; February 9-14, 2002; Seattle. Abstract 717.
911. Rhone SA, Hogg RS, Yip B, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: Results from a community-based study. *AIDS*. 1998;12:619–624.
912. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. *N Engl J Med*. 1987;317:192–197.
913. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. *J Virol*. 1994;68:1660–1666.
914. Rieckmann P, Poli G, Fox CH, et al. Recombinant gp120 specifically enhances tumor necrosis factor- α production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. *J Immunol*. 1991;147:2922–2927.
915. Rieckmann P, Poli G, Kehrl JH, et al. Activated B lymphocytes from human immunodeficiency virus–infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1. *J Exp Med*. 1991;173:1–5.
916. Rios A, Mansell P, Newell G, et al. Treatment of acquired immunodeficiency syndrome–related Kaposi's sarcoma with lymphoblastoid interferon. *J Clin Oncol*. 1985;3:506–512.
917. Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, Tebas P. Tenofovir Disoproxil Fumarate Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Individuals for Whom Interferon-alpha and Lamivudine Therapy Have Failed. *J Infect Dis*. 2002 Dec 15;186(12):1844-7.
918. Riviere Y, McChesney MB, Porrot F, et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. *AIDS Res Hum Retroviruses*. 1995;11:903–907.
919. Riviere Y, Tanneau-Salvadori F, Regnault A, et al. Human immunodeficiency virus–specific cytotoxic responses of seropositive individuals: Distinct types of effector cells mediate killing of targets expressing gag and env proteins. *J Virol*. 1989;63:2270–2277.
920. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. *N Engl J Med*, 2003. 349(24):2293-303.
921. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. *N Engl J Med*, 2003. 349(24):2293-303.
922. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. In: *Human retroviruses and AIDS 1999: a compilation and analysis of nucleic acid and amino acid sequences*.
923. Robinson WE, Kawamura T, Gorny MK, et al. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. *Proc Natl Acad Sci U S A*. 1990;87:3185–3189
924. Robinson WE, Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. *Lancet*. 1988;1:790–794.
925. Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Nadler M, Knechten H. Efficacy and Safety of bid firstline ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. 6th Conference on Retroviruses and Opportunistic Infections; Jan 31-Feb 4, 1999; Chicago. Abstract 631.
926. Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients. *J Acquir Immune Defic Syndr*. 2004 Jan 1;35(1):22-32.
927. Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients. *J Acquir Immune Defic Syndr*. 2004 Jan 1;35(1):22-32.
928. Rodriguez-Guardado A, Maradona JA, Carton JA, et al. *Pneumocystis carinii* prophylaxis can be discontinued after CD4⁺ cell recovery over 200 \times 106/l (Letter). *AIDS*. 1998;12:2355–2356.
929. Rogers MF, Ou CY, Rayfield M, et al. Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. *N Engl J Med*. 1989;320:1649–1654.
930. Rogers MF, Schochetman G, Hoff R. Advances in diagnosis of HIV infection in infants. In: Pizzo PA, Wilfert CM, eds. *Pediatric AIDS: The Challenge of HIV Infection in Infants, Children and Adolescents*. 2nd ed. Baltimore: Williams & Wilkins; 1994:219–238.
931. Rogo K, Kavoo-Linge. Human immunodeficiency virus seroprevalence among cervical cancer patients. *Gynecol Oncol*. 1990;37:87–92.
932. Roldan EO, Moskowitz L, Hensley GT. Pathology of the heart in AIDS. *Arch Pathol Lab Med*. 1987;111:943–946.

933. Romagnani S. Human TH1 and TH2 subsets: Regulation of differentiation and role in protection and immunopathology. *Int Arch Allergy Immunol.* 1992;98:279–285
934. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4⁺ T cell responses associated with control of viremia. *Science.* 1997;278:1447–1450.
935. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4⁺ T cell responses associated with control of viremia. *Science.* 1997;278:1447–1450.
936. Rosenberger DF, Serdarevic ON, Erlandson RA, et al. Successful treatment of microsporidial keratoconjunctivitis with topical fumagillin in a patient with AIDS. *Cornea.* 1993;12:261.
937. Rothenberg RB, Scarlett M, del Rio C, et al. Oral transmission of HIV. *AIDS.* 1998;12:2095–2105
938. Rowley JT, Anderson RM. Modelling the impact and cost-effectiveness of HIV prevention efforts. *AIDS* 1994; 8: 539-48.
939. Royce RA, Luckmann RS, Fusaro RE, et al. The natural history of HIV-1 infection: Staging classifications of disease. *AIDS.* 1991;5:355–364.
940. Rubbert A, Combadiere C, Ostrowski M, et al. Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry. *J Immunol.* 1998;160:3933–3941
941. Ruiz A, Ganz WI, Post MJ, et al. Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. *AJNR.* 1994;15:1885–1894.
942. Rusche JR, Javaherian K, McDanal C, et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. *Proc Natl Acad Sci U S A.* 1988;85:3198–3202.
943. Russian DA, Kovacs J. *Pneumocystis carinii* in Africa: An emerging pathogen? *Lancet.* 1995;346:1242–1243.
944. Rustin MHA, Ridely CM, Smith MD, et al. The acute exanthem associated with seroconversion to human T-cell lymphotropic virus III in a homosexual man. *J Infect Dis.* 1986;12:161–163.
945. Rutschmann O, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. *AIDS.* 1998;12:F71.
946. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. *AIDS.* 1998;12:F71–F77.
947. Ryder RW, Manzila T, Baende E, et al. Evidence from Zaire that breastfeeding by HIV-1 seropositive mothers is not a major route for perinatal HIV-1 transmission but does decrease morbidity. *AIDS.* 1991;5:709–714.
948. Ryder RW, Nsa W, Hassig SE, et al. Perinatal transmission of the human immunodeficiency virus type 1 to infants of seropositive women in Zaire. *N Engl J Med.* 1989;320:1637–1642.
949. Saag M, Knowles M, Chang Y, et al. Durable effect of VIRACEPT (nelfinavir mesylate, NFV) in triple combination therapy. Abstract I-101. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto; 1997.
950. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW, Rousseau F; FTC-301A Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. *JAMA.* 2004 Jul 14;292(2):180-9.
951. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW, Rousseau F; FTC-301A Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. *JAMA.* 2004 Jul 14;292(2):180-9.
952. Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW, Rousseau F; FTC-301A Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. *JAMA.* 2004 Jul 14;292(2):180-9.
953. Saah AJ, Hoover DR, Peng Y, et al. Predictors for failure of *Pneumocystis carinii* pneumonia prophylaxis. *JAMA.* 1995;273:1197–1202.
954. Safai B. Pathophysiology and epidemiology of epidemic Kaposi's sarcoma. *Semin Oncol.* 1987;2(Suppl 3):7–12.
955. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for *Pneumocystis carinii* pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. *J Infect Dis.* 1994;170:912–917.
956. Safrin, S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate *Pneumocystis carinii* pneumonia in patients with AIDS. A double blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. *Ann Intern Med.* 1996;124:792–802.
957. Saha K, Bentsman G, Chess L, et al. Endogenous production of beta-chemokines by CD4⁺, but not CD8⁺, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. *J Virol.* 1998;72:876–881.

958. Samson M, Labbe O, Mollereau C, et al. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. *Biochemistry*. 1996;35:3362–3367
959. Samson M, Libert F, Doranz B, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. *Nature*. 1996;382:722–725
960. Samuel MC, Hessel N, Shiboski S, et al. Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohorts. *J Acquir Immun Defic Syndr*. 1993;6:303.
961. Sanne I, Cahn P, Percival L, Phanuphaak P, Kelleher T, Wellens I, Giordano M, Pantaleo G, and the BMS-008 International Trial Group. Atazanavir vs Nelfinavir in Combination with Stavudine and Lamivudine in Treatment-Naive HIV-Infected Patients, 48-Week Results, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16-19, 2001, Abstract I-667.
962. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S; AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. *J Acquir Immune Defic Syndr*. 2003 Jan 1;32(1):18-29.
963. Sanne I, Quinn JB, Harris J, Shaw A, Hinkle J, Borroto-Esoda K, Moxham C, Rousseau F. Genotypic analysis of HIV-1 infected ART-naive patients receiving emtricitabine (FTC) or lamivudine (3TC) in a double blind equivalence trial. XIV International AIDS Conference, Barcelona, July 7-12, 2002. Abs TuPeB4433
964. Saracco A, Musicco M, Nicolosi A, et al. Man-to-women sexual transmission of HIV: Longitudinal study of 343 steady partners of infected men. *J Acquir Immune Defic Syndr*. 1993;6:497–502.
965. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Bein Community Programs for Clinical Research on AIDS. *N Engl J Med*. 1996;335:1099–1106.
966. Sargent S, Green S, Para M, et al. Sustained plasma viral burden reductions and CD4 increases in HIV-1 infected patients with rescriptor (DLV) + retrovir (ZDV) + epivir (3TC). Abstract 699. In: 5th Conference on Retroviruses and Opportunistic Infections. Chicago; 1998:209.
967. Sarnagadharan MG, Popovic M, Bruch L, et al. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. *Science*. 1984;224:506.
968. Sattler F, Briggs W, Antonipillai I, et al. Low dihydrotestosterone and weight loss in the AIDS wasting syndrome. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1998;18:246–251.
969. Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim-sulfamethoxazole versus pentamidine for therapy of *Pneumocystis* pneumonia: A prospective non-crossover study in patients with AIDS. *Ann Intern Med*. 1988;109:280–287.
970. Sattler FR, Frame P, Davis R, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of *Pneumocystis carinii* pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. *J Infect Dis*. 1994;170:165–172
971. Saville M, Lietzau J, Pluda J, et al. Activity of placlitaxel (Taxol) as therapy for HIV-associated Kaposi's sarcoma. *Lancet*. 1995;346:26–28.
972. Saville, R.D., N.T. Constantine, and Hansen C. Holm-et al. 1997. Evaluation of two novel immunoassays designed to detect HIV antibodies in oral fluids. *J Clin Lab Anal* 11:63-68.
973. Scala E, D'Offizi G, Rosso R, et al. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. *J Immunol*. 1997;158:4485–4492.
974. Scarlatti G, Leitner T, Hodara V, et al. Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. *Immunol Lett*. 1996;51:23–28.
975. Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. *Ann Intern Med*. 1996;125:257–264.
976. Schacker T. Primary HIV infection. Early diagnosis and treatment are critical to outcome. *Postgrad Med*. 1997;102(4):143–146, 149–151.
977. Schacker TW, Hughes JP, Shea T, et al. Biological and virologic characteristics of primary HIV infection. *Ann Intern Med*. 1998;128:613
978. Schalling M, Ekman M, Kaaya EE, et al. A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. *Nat Med*. 1995;1:707–708.
979. Schneider M, Borleffs JC, Stolk RP, et al. Discontinuation of prophylaxis for *Pneumocystis carinii* pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy. *Lancet*. 1999;353:201–203.
980. Schneider MME, Hoepelman AIM, Eeftinck Schattenkerk JKM, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against *Pneumocystis carinii* pneumonia in patients with human immunodeficiency virus infection. *N Engl J Med*. 1992;327:1836–1841

981. Schneider MME, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against *Pneumocystis carinii* pneumonia in patients with human immunodeficiency virus. *J Infect Dis.* 1995; 171:1632–1636.
982. Schnittman SM, Greenhouse JJ, Psallidopoulos MC, et al. Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. *Ann Intern Med.* 1990;113:438–443.
983. Schnittman SM, Psallidopoulos MC, Lane HC, et al. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. *Science.* 1989;245:305–308.
984. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. *N Engl J Med.* 1989;321:874–879
985. Schooley R, Ruane P, Myers R, Beall G, Lampiris H, Berger D, Chen SS, Miller M, Isaacson E, Cheng A, FOR THE STUDY 902 TEAM. Tenofovir DF: an interim analysis of the open label extension phase from a 48 Week, randomized, double blind, placebo controlled study in antiretroviral experienced patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago. Abstract 1920.
986. Schramm, W., G.B. Angulo, and P.C. Torres, et al. A simple saliva-based test for detecting antibodies to Human Immunodeficiency Virus. *Clin Diag Lab Immunol* 1999; 6: 577-580.
987. Schultz AM, Bradac JA. The HIV vaccine pipeline, from preclinical to phase III. *AIDS* 2001; 15: (suppl 5) S147-58
988. Schumann D, Gathe J, Sanne I, and Wood R on behalf of the SOLO Study Team. Efficacy and Safety of GW433908/Ritonavir Once Daily in Therapy Naive Subjects (The SOLO Study): 48 Week Results. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom, November 17 - 21, 2002. Abstract PL14.4.
989. Schumann D, Gathe J, Sanne I, and Wood R on behalf of the SOLO Study Team. Efficacy and Safety of GW433908/Ritonavir Once Daily in Therapy Naive Subjects (The SOLO Study): 48 Week Results. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom, November 17 - 21, 2002. Abstract PL14.4.
990. Schupbach J, Popovic M, Gilden RV, et al. Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. *Science.* 1984;224:503.
991. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). *J Infect Dis.* 1995;171:1411–1419.
992. Schwartlander B, Stover J, Walker N, et al. Resource needs for HIV/AIDS. *Science* 2001; 292: 2434-36.
993. Schwartz O, Marechal V, Gall SL, et al. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. *Nat Med.* 1996;2:338–342.
994. Sei Y, Tsang PH, Chu FN, et al. Inverse relationship between HIV-1 p24 antigenemia, anti-p24 antibody and neutralizing antibody response in all stages of HIV-1 infection. *Immunol Lett.* 1989;20:223–230.
995. Sei Y, Tsang PH, Roboz JP, et al. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: A double-blind study. *J Clin Immunol.* 1988;8:464–472.
996. Seidlin M, Vogler M, Lee E, et al. Heterosexual transmission of HIV in a cohort of couples in New York City. *AIDS.* 1993;7:1247.
997. Selik RM, Castro KG, Pappaioanou M, et al. Birthplace and the risk of AIDS among Hispanics in the United States. *Am J Public Health.* 1989;79:836–839.
998. Selnes OA, Galai N, Bacellar H, et al. Cognitive performance after progression to AIDS: A longitudinal study from the Multicenter AIDS Cohort Study. *Neurology.* 1995;45:267–275.
999. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. *Lancet.* 1998 351:228–229.
1000. Shafer RW, Edlin BR. Tuberculosis in patients infected with human immunodeficiency virus: Perspective on the past decade. *Clin Infect Dis.* 1996;22:683–704
1001. Shafer RW, Edlin BR. Tuberculosis in patients infected with human immunodeficiency virus: Perspective on the past decade. *Clin Infect Dis.* 1996;22:683–704.
1002. Sharman A. HIV testing in population-based surveys. *ORC Macro*, 2002
1003. Sharman, A. Knowledge and attitudes toward HIV/AIDS and other sexually transmitted infections. In: 1999 Kazakhstan Demographic and Health Survey. Academy of Preventive Medicine of Kazakhstan and ORC Macro, 2000.
1004. Sharpstone D, Rowbottom A, Nelson M, et al. The treatment of microsporidial diarrhea with thalidomide. *AIDS.* 1995;9:658
1005. Shaw GM, Hahn BH, Arya SK, et al. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. *Science.* 1984;226:1165–1171.
1006. Sherry B, Zybarth G, Alfano M, et al. Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes. *Proc Natl Acad Sci U S A.* 1998;95:1758.

1007. Silvestris F, Williams RC, Dammacco F. Autoreactivity in HIV-1 infections: The role of molecular mimicry. *Clin Immunol Immunopathol.* 1995;75:197–205
1008. Simon DM, Cello JP, Valenzuela J, et al. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. *Gastroenterology.* 1995;108:1753.
1009. Simpson DM, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: Results of a placebo-controlled trial. *Neurology.* 1997;47:1254–1259.
1010. Skowron G, Cole B, Zheng D, et al. gp120-directed antibody-dependent cellular cytotoxicity as a major determinant of the rate of decline in CD4 percentage in HIV-1 disease. *AIDS.* 1997;11:1807–1814.
1011. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant *Mycobacterium tuberculosis* in patients with advanced HIV infection. *N Engl J Med.* 1993;328:1137–1144.
1012. Smith DE, Forbes A, Davies S, et al. Diagnosis of *Pneumocystis carinii* pneumonia in HIV antibody positive patients by simple outpatient assessments. *Thorax.* 1992;47:1005–1009
1013. Smithgall M, Wong J, Critchett K, et al. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. *J Immunol.* 1996;156:2324–2330
1014. Snider WD, Simpson DM, Nielsen S, et al. Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patients. *Ann Neurol.* 1983;14:403–418.
1015. Snow A, Harris J, Borroto-Esoda K, Mondou E, Sorbel J, Dalton M, and Rousseau F. Efavirenz therapy for hepatitis infection with HIV+ patients co-infected with hepatitis B virus: Efficacy and genotypic findings in antiretroviral treatment-naive patients. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004. Abstract 836.
1016. Sodroski J, Goh WC, Rosen K, et al. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. *Nature.* 1986;322:470–474.
1017. Somasundaran M, Robinson HL. Unexpectedly high levels of HIV-1 RNA and protein synthesis in a cytotoxic infection. *Science.* 1988;242:1554–1557.
1018. Soto-Ramirez LE, Renjifo B, McLane MF, et al. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. *Science.* 1996;271:1291–1293.
1019. Soulier J, Grothet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. *Blood.* 1995;86:1276–1280.
1020. Sparano JA, Wiernik PH, Hu X, et al. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. *J Clin Oncol.* 1996;14:3026–3035
1021. Spear GT, Kessler HA, Rothberg L, et al. Decreased oxidative burst activity of monocytes from asymptomatic HIV-infected individuals. *Clin Immunol Immunopathol.* 1990;54:184–191.
1022. Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. *J Exp Med.* 1996;183:215–225.
1023. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. *Ann Intern Med.* 1997;126:355–363.
1024. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV. *J Acquir Immune Defic Syndr.* 2004 Aug 15;36(5):1011-1019.
1025. Squires K, Pierone G, Berger D, Steinhart C, Bellos N, Becker S, Salzer J, Coakley D, Chen S, Miller M, Cheng A, For the Study 907 Team. Tenofovir DF: A 24-Week Interim Analysis from a Phase III Double Blind, Placebo Controlled Study in Antiretroviral Experienced Patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago. Abstract I666.
1026. Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). *AIDS* 2000;14:1591-600.
1027. St. Louis ME, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. *JAMA.* 1993;269:2853–2859
1028. Stamm W, et al. Association between genital ulcer disease and acquisition of HIV infection in homosexual men. *JAMA.* 1988;260:1429
1029. Stamm WE, Handsfield HH, Rompalo AM, et al. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. *JAMA.* 1988;260:1429–1433.
1030. Stanley S, McCune J, Kaneshima H, et al. Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. *J Exp Med.* 1993;178:1151–1163.
1031. Stanley S, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. *N Engl J Med.* 1996;334:1222–1230.

1032. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of *Pneumocystis carinii* pneumonia in HIV-infected persons. *Am J Respir Crit Care Med*. 1997;155:60–66.
1033. Staprans S, Hamilton B, Follansbee S, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. *J Exp Med*. 1995;182:1727–1737.
1034. Staszewski S, DeMasi R, Hill AM, Dawson D. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. *AIDS*. 1998;12:1991–1997.
1035. Staszewski S, Katlama C, Harrer T, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naïve subjects. *AIDS*. 1998;12:F197–F202.
1036. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. *JAMA*. 1996;276:111–117.
1037. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. *N Engl J Med* 1999;341:1865–73.
1038. Stern Y, Liu X, Marder K, et al. Neuropsychological changes in a prospectively followed cohort of homosexual and bisexual men with and without HIV infection. *Neurology*. 1995;45:467–472.
1039. Stevens DA. Coccidioidomycosis. *N Engl J Med*. 1995;332:1077
1040. Stover J, Walker N, Garnett GP, Salomon JA, Stanecki KA, Ghys PD, Grassly NC, Anderson RM, Schwartländer B. Can we reverse the HIV/AIDS pandemic with an expanded response? *Lancet* 2002; 360: 73–77
1041. Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of human immunodeficiency virus–associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group protocol 142—Low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. *J Clin Oncol*. 1998;16:3601–3606
1042. Strawford A, Hellerstein M. The etiology of wasting in the human immunodeficiency virus and acquired immunodeficiency syndrome. *Semin Oncol*. 1998;25(2 Suppl 5):76–81.
1043. Stringer JR, Walzer PD. Molecular biology and epidemiology of *Pneumocystis carinii* infection in AIDS. *AIDS*. 1996;10:561–571
1044. Sulkowski M, Chaisson RE, Karp CL, et al. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. *J Infect Dis*. 1998;178:1642–1648.
1045. Sykes A, Wakeford C, Rousseau F, Rigney A, Mondou E. Antiviral Efficacy and Rate of Development of Resistance in Patients Treated 1 Year for Chronic HBV Infection with FTC. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24–28, 2002. Abstract 674-M.
1046. Taburet AM, Piketty C, Gerard L, Vincent I, Chazallon C, Clavel F, Calvez V, Aboulker JP, Girard PM. Pharmacokinetic Parameters of Atazanavir/Ritonavir when Combined to Tenofovir in HIV Infected Patients with Multiple Treatment Failures: A Sub-study of Puzzle2-ANRS 107 Trial. 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston. Abstract 537.
1047. Tackett D, Child M, Agarwala S, Geiger M, Geraldles M, Laura B, O'Mara E. Atazanavir: A Summary of Two Pharmacokinetic Drug Interaction Studies in Healthy Subjects 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003. Abstract 543
1048. Tackett D, Child M, Agarwala S, Geiger M, Geraldles M, Laura B, O'Mara E. Atazanavir: A Summary of Two Pharmacokinetic Drug Interaction Studies in Healthy Subjects 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003. Abstract 543
1049. Tanneau F, McChesney M, Lopez O, et al. Primary cytotoxicity against the envelope glycoprotein of human immunodeficiency virus-1: Evidence for antibody-dependent cellular cytotoxicity in vivo. *J Infect Dis*. 1990;162:837–843.
1050. Taylor JM, Fahey JL, Detels R, et al. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: Which to choose and how to use. *J Acquir Immun Defic Syndr*. 1989;2:114–124.
1051. Tebas P, Patick AK, Kane EM, Klebert MK, Simpson JH, Erice A, Powderly WG, Henry K. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. *AIDS* 1999;13:F23–8.
1052. Tee W, Mijch A. *Campylobacter jejuni* bacteremia in human immunodeficiency (HIV)–infected and non–HIV-infected patients: Comparison of clinical features and review. *Clin Infect Dis*. 1998;26:91–96
1053. Temmerman M, Mohammed Ali F, Ndinya-Achola JO, et al. Rapid increase of both HIV-1 infection and syphilis among pregnant women in Nairobi, Kenya. *AIDS*. 1992;6:1181–1185.
1054. Terai C, Kornbluth RS, Pauza CD, et al. Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. *J Clin Invest*. 1991;87:1710–1715
1055. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies. *N Engl J Med*. 1999;340:977–987

1056. The World Bank. World Development Report 1993: Investing in Health. New York: Oxford University Press; 1993.
1057. Theodorou I, Meyer L, Magierowska M, et al. HIV-1 infection in an individual homozygous for CCR5 Δ 32. *Lancet*. 1997;349:1219–1220
1058. Theuer CP, Hopewell PC, Elias D, et al. Human immunodeficiency virus infection in tuberculosis patients. *J Infect Dis*. 1990;162:8–12.
1059. Thiry L, Sprecher-Goldberger S, Jonckheer T, et al. Isolation of AIDS virus from cell-free breast milk of three healthy virus carriers (Letter). *Lancet*. 1985;2:891–892.
1060. Thompson JL, Yager TJ, Martin JL. Estimated condom failure and frequency of condom use among gay men. *Am J Public Health*. 1993;83:1409–1413.
1061. Thomson MM, Delgado E, Herrero I, Villahermosa ML, Vázquez de Parga E, Cuevas MT, et al. Diversity of mosaic structures and common ancestry of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Argentina revealed by analysis of near full-length genome sequences. *J Gen Virol* 2002; 83: 107-19.
1062. Thomson MM, Delgado E, Manjón N, et al. HIV-1 genetic diversity in Galicia, Spain: BG intersubtype recombinant viruses are circulating among injecting drug users. *AIDS* 2001; 15: 509-16.
1063. Thomson MM, Nájera R. Travel and the introduction of human immunodeficiency virus type 1 non-B subtype genetic forms into Western countries. *Clin Infect Dis* 2001; 32: 1732-37.
1064. Thomson MM, Villahermosa ML, Vázquez-de Parga E, et al. Widespread circulation of a B/F intersubtype recombinant form among HIV-1-infected individuals in Buenos Aires, Argentina. *AIDS* 2000; 14: 897-99.
1065. Thomson, M, Pérez-Álvarez, L, and Nájera, R Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. *The Lancet*, 2002; Volume 2, Number 8
1066. Tindall B, Barker S, Donovan B, et al. Characteristics of the acute clinical illness associated with human immunodeficiency virus infection. *Arch Intern Med*. 1988;148:945–949.
1067. Tipranavir Review Team (HFD-530), Memorandum to FDA Antiviral Advisory Committee Members/Guests. April 22, 2005. Available at: www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4139b1-01-fda.pdf
1068. Tirelli U, Vaccher E, Rezza G, et al. Hodgkin's disease and infection with the human immunodeficiency virus in Italy. *Ann Intern Med*. 1988;108:309
1069. Tirelli U, Vaccher E, Sinicco A, et al. Forty-nine unusual HIV-related malignant tumors. Program of the 5th International Conference on AIDS, Montreal, 1989.
1070. Tokars JI, Bell DM, Culver DH, et al. Percutaneous injuries during surgical procedures. *JAMA*. 1992;267:2899–2904.
1071. Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. *Ann Intern Med*. 1993;118:913–919
1072. Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. *Ann Intern Med*. 1993;118:913–919.
1073. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. *N Engl J Med*. 1997;336:1531–1532.
1074. Torres RA, Winberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. *Clin Infect Dis*. 1997;24:422.
1075. Torseth JW, Berman PW, Merigan TC. Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals. *AIDS Res Hum Retroviruses*. 1988;4: 23–30.
1076. Tran JQ, Petersen C, Garrett MK, Schultz-Smith MD, Lillibridge JH, Kerr BM. The pharmacokinetics (PK) and tolerability of indinavir (IDV) and delavirdine (DLV) administered twice-daily (BID) in the absence and presence of food in healthy volunteers. Abstract 1634. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2000; Toronto.
1077. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. *Immunol Today*. 1993;14:335–338
1078. Trussell J, Warner DL, Hatcher R. Condom performance during vaginal intercourse: Comparison of TrojanEnz and Tactylon condoms. *Contraception*. 1992;45:11–19
1079. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus–infected patients. *J Infect Dis*. 1998;177:1080–1083.
1080. Turner R, Levine A, Gill P, et al. Progressive histopathologic abnormalities in the persistent generalized lymphadenopathy syndrome. *Am J Surg Pathol*. 1987;11:625–632.
1081. Tyler DS, Nastala CL, Stanley SD, et al. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo and cytophilic antibody. *J Immunol*. 1989;142:1177–1182.
1082. Tyler DS, Stanley SD, Zolla-Pazner S, et al. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. *J Immunol*. 1990;145:3276–3282.
1083. Tyler KL, Sandberg E, Baum KF. Medial medullary syndrome and meningovascular syphilis: A case report in an HIV-infected man and a review of the literature. *Neurology*. 1994;44:2231–2235.
1084. Tzipori S, Robertson D, Chapman C. Remission of diarrhea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum. *BMJ*. 1986;293:2283.

1085. Ullum H, Gotzsche PC, Victor J, et al. Defective natural immunity: An early manifestation of human immunodeficiency virus infection. *J Exp Med.* 1995;182:789–799.
1086. Ullum H, Lepri A, Victor J, et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1 beta are associated with a decreased risk of HIV disease progression. *J Infect Dis.* 1998;177:331–336.
1087. UNAIDS and WHO. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization. Revised recommendations for the selection and use of HIV antibody tests. *Wkly Epidemiol Rec* 1997; 72: 81-88.
1088. UNAIDS, WHO. AIDS epidemic update: December 2001. Geneva: UNAIDS, 2001.
1089. UNAIDS. A measure of success in Uganda: The value of monitoring both HIV prevalence and sexual behaviour. Geneva: UNAIDS Best Practice Collection, UNAIDS; 1998a.
1090. UNAIDS. Connecting lower HIV infection rates with changes in sexual behaviour in Thailand: Data collection and comparison. Geneva: UNAIDS Best Practice Collection, UNAIDS; 1998b.
1091. UNAIDS. HIV and infant feeding: An interim statement. *Wkly Epidemiol Rec.* 1996;71:289–291.
1092. UNAIDS. Trends in HIV incidence and prevalence: Natural course of the epidemic or results of behavioral change? Geneva: UNAIDS, 1999.
1093. UNAIDS/WHO. 2000. Guidelines for second generation HIV surveillance. UNAIDS/WHO Global Group on HIV/AIDS and STI Surveillance. Geneva, Switzerland: UNAIDS/WHO.
1094. Ungar BLP, Ward DJ, Fayer R, et al. Cessation of *Cryptosporidium*-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum. *Gastroenterology.* 1990;98:486.
1095. United Nations. Declaration of commitment on HIV/AIDS: global crisis--global action. New York: United Nations Special Session on HIV/AIDS, June 25-27, 2001.
1096. Urnovitz, H., J. Sturge, T. Gottfried, and W. Murphy. Urine antibody tests: New insights into the dynamics of HIV-1 infection. *Clin Chem* 1999; 45: 1602-1613.
1097. Vaccher E, Tirelli U, Spina M, et al. Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: A single-institute study of 96 patients. *J Clin Oncol.* 1996;14:2217–2223.
1098. Valentin A, Gegerfelt AV, Matsuda S, et al. In vitro maturation of mononuclear phagocytes and susceptibility to HIV-1 infection. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1991;4:751–759.
1099. Valentin A, Lu W, Rosati M, et al. Dual effect of interleukin 4 on HIV-1 expression: Implications for viral phenotypic switch and disease progression. *Proc Natl Acad Sci U S A.* 1998;95:8886–8891.
1100. Van de Perre P, Simonon A, Msellati P, et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. *N Engl J Med.* 1991;325:593–598.
1101. van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M, Pavia AT, Schmidt RE, Gonzalez-Lahoz J, Montaner J, Antunes F, Gulick R, Banhegyi D, van der Valk M, Reiss P, van Weert L, van Leth F, Johnson VA, Sommadossi JP, Lange JM. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. *AIDS* 2003; 17(7):987-999.
1102. Van Leth F, Hassink E, Phanuphak P, Miller S, Gazzard B, Cahn P, Wood R, Squires K, Katlama C, Santos B, Robinson P, van Leeuwen R, Wit F, and Lange J. Results of the 2NN Study: A Randomized Comparative Trial of First-line Antiretroviral Therapy with Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together with Stavudine and Lamivudine. 10th CROI, Abstract 176. February 2003.
1103. Vidal N, Peeters M, Mulanga-Kabeya C, et al. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. *J Virol* 2000; 74: 10498-104507.
1104. Vigano A, Balotta C, Trabattoni D, et al. Virologic and immunologic markers of disease progression in pediatric HIV infection. *AIDS Res Hum Retroviruses.* 1996;12:1255–1262.
1105. Volberding P, Kusick P, Feigal D. Effects of chemotherapy for HIV-associated Kaposi's sarcoma on long-term survival (Abstract 11). *Proc Am Soc Clin Oncol.* 1989;8:3.
1106. Volberding P, Mitsuyasu R, Golando J, et al. Treatment of Kaposi's sarcoma with interferon alfa-2 (Intron A). *Cancer.* 1987;59:620–625.
1107. Volberding P, Mitsuyasu R. Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma. *Semin Oncol.* 1985;2(Suppl 5):2–6.
1108. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. *N Engl J Med.* 1990;322:941–949.
1109. Volm M, Von Roenn J. Non-AIDS-defining malignancies in patients with HIV infection. *Curr Opin Oncol.* 1996;8:386–391.
1110. Vyakarnam A, Matear P, Martin S, et al. Th1 cells specific for HIV-1 gag p24 are less efficient than Th0 cells in supporting HIV replication, and inhibit virus replication in Th0 cells. *Immunology.* 1995;86:85–96

1111. Wachtel T, Piette J, Mor V. Quality of life in persons with human immunodeficiency virus infection: Measurement by the medical outcomes study instrument. *Ann Intern Med.* 1992;116:129–137.
1112. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE, Cherrington JM. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. *Antivir Ther* 1999;4:87-94.
1113. Wakeford C, Shen G, Hulett L, Quinn JB, Rousseau F. Long-term Efficacy and Safety of Emtricitabine in HIV+ Adults Switching from a Lamivudine Containing HAART Regimen. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003. Abstract 550.
1114. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. *Nature.* 1987;328:345–348.
1115. Walker BD, Flexner C, Paradis TJ, et al. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. *Science.* 1988;240:64–66.
1116. Walker CM, Erickson AL, Hsueh FC, et al. Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism. *J Virol.* 1991;65:5921–5927.
1117. Walker CM, Levy JA. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. *Immunology.* 1989;66:628–630.
1118. Walker CM, Moody DJ, Stites DP, et al. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. *Science.* 1986;234:1563–1566.
1119. Walker DJ, Wakefield AE, Dohn MN, et al. Sequence polymorphism in the *Pneumocystis carinii* cytochrome b gene and thus association with atovaquone failure. *J Infect Dis.* 1998;178:1767–1775.
1120. Wallace JM, Hansen NI, Lavange L, et al. Respiratory disease trends in the pulmonary complications of HIV infection study cohort. *Am J Respir Crit Care Med.* 1997;155:72–80.
1121. Wallace JM, Rao AV, Glassroth J, et al. Respiratory illness in persons with human immunodeficiency virus infection. *Am Rev Respir Dis.* 1993;148:1523–1529
1122. Walmsley S, Leith J, Katlama C, et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone and in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): Interim analysis of B1182.51. In: Program and abstracts of the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WeOrB1236.
1123. Ward JW, Deppe DA, Samson S, et al. Risk of human immunodeficiency virus infection from blood donors who later developed the acquired immunodeficiency syndrome. *Ann Intern Med.* 1987;106:61–62.
1124. Waskin H, Stehr-Green JK, Helmick CG, et al. Risk factors for hypoglycemia associated with pentamidine therapy for *Pneumocystis pneumonia*. *JAMA.* 1988;260:345–347.
1125. Weinberg JB, Mathews TJ, Cullen BR, et al. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. *J Exp Med.* 1991;174:1477–1482.
1126. Weinhold KJ, Lyerly HK, Matthews TJ, et al. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. *Lancet.* 1988;1:902–905.
1127. Weinhold KJ, Lyerly HK, Stanley SD, et al. HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. *J Immunol.* 1989;142:3091–3097.
1128. Weissman D, Poli G, Fauci AS. IL-10 synergizes with multiple cytokines in enhancing HIV production in cells of monocytic lineage. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1995;9:442–449.
1129. Weller SC. A metaanalysis of condom effectiveness in reducing sexually transmitted HIV. *Soc Sci Med.* 1993;36:1635–1644.
1130. Welles SL, Jackson JB, Yen-Lieberman B, et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) disease and with little or no prior zidovudine therapy. *J Infect Dis.* 1996;174:696–703.
1131. Wells MA, Wittek AE, Epstein JS, et al. Inactivation and partition of human T-cell lymphotropic virus, type III, during ethanol fractionation of plasma. *Transfusion.* 1986;26:210–213
1132. Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 tat and gp120. *Nature.* 1995;375:497–500
1133. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. *Am J Med.* 1995;98:336
1134. Wheat LJ, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. The National Institute of Allergy and Infectious Diseases Clinical Trials and Mycoses Study Group Collaborators. *Ann Intern Med.* 1993;118:610–616.
1135. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. *Lancet.* 1995;346:799–802.
1136. WHO-UNAIDS Network for HIV Isolation and Characterization Osmanov S, Pattou C, Walker N, Schwarlander B, Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. *J Acquir Immune Defic Syndr* 2000; 29: 184-90.
1137. WHO-UNAIDS. Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1. Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee. Geneva, 21–23 February 2000. *AIDS* 2001; 15: W1–W255.

1138. Wilson IB, Cleary PD. Clinical predictors of functioning in persons with acquired immunodeficiency syndrome. *Med Care*. 1996;34:610–623.
1139. Wilson J, Ogg G, Allen R, et al. Oligoclonal expansions of CD8+ T cells in chronic HIV infection are antigen specific. *J Exp Med*. 1998;188:785–790.
1140. Wire MB, Ballow C, Preston SL, Hendrix CW, Piliero PJ, Lou Y, Stein DS. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. *AIDS*. 2004 Apr 9;18(6):897–907.
1141. Wire MB, Preston SL, Ballow C, Hendrix CW, Lou Y, Piliero P, Stein DS. An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two gw433908 (908) and Ritonavir (RTV) QD Regimens in Combination with Efavirenz (EFV) in Healthy Adult Subjects (APV10009). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 16-19, 2001. Abstract I-1737.
1142. Wiselka MJ, Nicholson KG, Ward SC, Flower AJE. Acute infection with human immunodeficiency virus associated with facial nerve palsy and neuralgia. *J Infect*. 1987;15:189–194.
1143. Wong ES, Stotka JL, Chinchilli VM, et al. Are universal precautions effective in reducing the number of occupational exposures among health care workers? A prospective study of physicians on a medical service. *JAMA*. 1991;265:1123–1128.
1144. Wong MC, Suite NDA, Labar DR. Seizures in human immunodeficiency virus infection. *Arch Neurol*. 1990;47:640–642.
1145. Wong MT, Warren RQ, Anderson SA, et al. Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1–uninfected subjects. *J Infect Dis*. 1993;168:1523–1527.
1146. Wong-Staal F. Human immunodeficiency viruses and their replication. In: Fields BN, ed. *Virology*. 2nd ed. New York: Raven Press; 1990:1529.
1147. World Health Organization. Consensus statement from the WHO/UNICEF consultation on HIV transmission and breast-feeding. *Wkly Epidemiol Rec*. 1992; 67:177–179.
1148. Wright DN, Nelson RP Jr, Ledford DK, et al. Serum IgE and human immunodeficiency virus (HIV) infection. *J Allergy Clin Immunol*. 1990;85:445–452.
1149. Wyatt R, Sodroski J. The HIV-1 envelope glycoprotein: Fusogens, antigens, and immunogens. *Science*. 1998;280:1884
1150. Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides [published erratum appears in *N Engl J Med*. 1990;322:280]. *N Engl J Med*. 1989;321:726–738.
1151. Yerly S, Perneger TV, Hirschel B, et al. A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. The Swiss HIV Cohort Study. *Arch Intern Med*. 1998;158:247–252.
1152. Yoffe B, Lewis DE, Petrie BL, et al. Fusion as a mediator of cytolysis in mixtures of uninfected CD4+ lymphocytes and cells infected by human immunodeficiency virus. *Proc Natl Acad Sci U S A*. 1987;84:1429–1433.
1153. Yoo J, Chen H, Kraus T, et al. Altered cytokine production and accessory cell function after HIV-1 infection. *J Immunol*. 1996;157:1313–1320.
1154. Yorke JA, Heathcote HW, Nold A. Dynamics and control of the transmission of gonorrhoea. *Sex Transm Dis*. 1978;5:31–37.
1155. Youle M, Gerstoft J, Fox Z, Losso M, Jayaweera DT, Rieger A, Brunn JN, Castagna A, Walmsley S, Hill A, Dragsted UB, Lundgren JD. The final Week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg, bid) versus saquinavir/ritonavir (1000/100 mg bid). Abstract LB23. 2nd International AIDS Society Conference. July 13-16, 2003. Paris.
1156. Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. *Cell*. 1990;61:213–222.
1157. Zagury D, Lachgar A, Chams V, et al. C-C chemokines, pivotal in protection against HIV type 1 infection. *Proc Natl Acad Sci U S A*. 1998;95:3857–3861.
1158. Zambruno G, Giannetti A, Bertazzoni U, et al. Langerhans cells and HIV infection. *Immunol Today*. 1995;16:520–524.
1159. Zarling JM, Ledbetter JA, Sias J, et al. HIV-infected humans, but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected CD4+ cells. *J Immunol*. 1990;144:2992–2998.
1160. Zaw, M. et al. Local evaluation of a rapid HIV assay for use in developing countries. *Trop Med and Intern. Health* 1999; 4: 216-221.
1161. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. *N Engl J Med*. 1998;339:1803–1809.
1162. Zhou P, Goldstein S, Devadas K, et al. Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV infection: Inhibition of mRNA expression. *Nat Med*. 1997;3:659–664
1163. Zhu T, Korber BT, Nahmias AJ, et al. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. *Nature*. 1998;391:594–597

1164. Ziegler J, Beckstead J, Volberding P, et al. Non-Hodgkin's lymphoma in 90 homosexual men: Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. *N Engl J Med.* 1984;311:565–570.
1165. Ziegler J, Templeton AC, Vogel CL. Kaposi's sarcoma: A comparison of classical, endemic, and epidemic forms. *Semin Oncol.* 1984;11:47–52.
1166. Zimmerman P, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial backgrounds and quantified risks. *Mol Med.* 1997;3:23–36.
1167. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. *Ann Intern Med* 1999;131:813-21.